ERBB2 Gene

Aliases
for ERBB2 gene

Previous GC identifers: GC17P037262 GC17P039854 GC17P037766 GC17P038231 GC17P035109 GC17P033638

Summaries
for ERBB2 gene

Genomic Views
for ERBB2 gene

RefSeq DNA sequence:

NC_000017.10  NC_018928.1  NT_010783.15  

SwitchGear Promoter luciferase reporter plasmids (see all 3): ERBB2 promoter sequence

QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays in human, mouse, rat ERBB2

ERBB2 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)


GeneLoc information about chromosome 17         GeneLoc Exon Structure

GeneLoc location for GC17P037844:  view genomic region     (about GC identifiers)

Proteins
for ERBB2 gene

6/17 PDB 3D structures from and Proteopedia for ERBB2 (see all 17):

1MFG (3D)        1MFL (3D)        1MW4 (3D)        1N8Z (3D)        1OVC (3D)        1QR1 (3D)    

Explore the universe of human proteins at neXtProt for ERBB2: NX_P04626

Post-translational modifications:

	EMD Millipore Purified and/or Recombinant ERBB2 Protein
	R&D Systems Recombinant & Natural Proteins for ERBB2 (ErbB2/Her2)
	Enzo Life Sciences proteins for ERBB2
	OriGene Purified Proteins (see all 5): ERBB2 OriGene Protein Over-expression Lysate: ERBB2 OriGene Custom Protein Services for ERBB2
	GenScript Custom Purified and Recombinant Proteins Services for ERBB2
	Novus Biologicals ERBB2 Proteins Novus Biologicals ERBB2 Lysate
	Browse Sino Biological Recombinant Proteins
	ProSpec Recombinant Protein for ERBB2
	Uscn Proteins for ERBB2

Gene Ontology (GO): 5/15 cellular component terms (GO ID links to tree view) (see all 15):    About this table

	EMD Millipore Mono- and Polyclonal Antibodies for the study of ERBB2
	R&D Systems Antibodies for ERBB2 (ErbB2/Her2)
	Cell Signaling Technology (CST) Antibodies for ERBB2  (HER2)
	OriGene Antibodies (see all 34): ERBB2 OriGene Custom Antibody Services for ERBB2
	GenScript Superior Antibodies for ERBB2
	Novus Biologicals ERBB2 Antibodies
	Abcam antibodies for ERBB2
	Uscn Antibodies for ERBB2
	ThermoFisher Antibody for ERBB2

	EMD Millipore Kits and Assays for the Analysis of ERBB2
	OriGene Custom Immunoassay Development Browse OriGene Fluorogenic Cell Assay Kits
	R&D Systems ELISAs for ERBB2 (ErbB2/Her2)         (see all)
	GenScript Custom Assay Services for ERBB2
	Cell Signaling Technology (CST) Sandwich ELISA Kits for ERBB2 (HER2)
	Browse Enzo Life Sciences for kits & assays
	Uscn ELISAs and CLIAs for ERBB2

Protein Domains /
Families
for ERBB2 gene

ProtoNet protein and cluster: P04626

Function
for ERBB2 gene

miRNA Products:		miRTarBase miRNAs that target ERBB2: hsa-mir-125b (MIRT002939), hsa-mir-331-3p (MIRT005805), hsa-mir-125a-5p (MIRT005118), hsa-mir-559 (MIRT000036), hsa-mir-21 (MIRT004318), hsa-mir-548d-3p (MIRT000037)
		OriGene 3'-UTR Clone (see all 2): ERBB2 Browse MicroRNA Expression Plasmids
		QIAGEN Custom miScript Target Protector blocks miRNA-binding site of human, mouse, rat ERBB2
		8/11 QIAGEN miScript miRNA Assays for microRNAs that regulate ERBB2 (see all 11):
		hsa-miR-548d-3p hsa-miR-3664-5p hsa-miR-452* hsa-miR-3921 hsa-miR-221* hsa-miR-146a* hsa-miR-593 hsa-miR-518a-5p
		SwitchGear 3'UTR luciferase reporter plasmid: ERBB2 3' UTR sequence

Inhib. RNA Products:		Browse for Gene Knock-down Tools from EMD Millipore
		OriGene 29mer shRNA kits in GFP-retroviral vector in human, mouse, rat for ERBB2 (see all 7) OriGene shRNA RFP: ERBB2 OriGene siRNA: ERBB2
		QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat ERBB2

Gene Editing Products:

DNA2.0 Custom Protein Engineering Service for ERBB2

Clone Products:		Browse Clones for the Expression of Recombinant Proteins Available from EMD Millipore
		OriGene Myc/DDK tagged cDNA clones in CMV expression vector in human, mouse, rat for ERBB2 (see all 6) OriGene untagged cDNA clones in CMV expression vector in human, mouse, rat for ERBB2 (see all 4) OriGene custom cloning services – gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
		GenScript: all cDNA clones in your preferred vector (see all 2): ERBB2 (NM_004448)
		Sino Biological Human cDNA Clone for ERBB2
		DNA2.0 Custom Codon Optimized Gene Synthesis Service for ERBB2
		Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat ERBB2

Cell Line Products:		GenScript Custom overexpressing Cell Line Services for ERBB2
		Search LifeMap BioReagents cell lines for ERBB2

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for ERBB2

Gene Ontology (GO): 5/19 molecular function terms (GO ID links to tree view) (see all 19):    About this table

15/19 MGI mutant phenotypes (inferred from 17 alleles) (MGI details for Erbb2)

Pathways & Interactions
for ERBB2 gene

	Super-pathway	contained gene-specific pathways
1	Signaling by FGFR	8/12 pathways (see all 12) Signaling by FGFR 1.00 DAP12 signaling 0.83 Downstream signaling of activated FGFR 0.92 Signaling by EGFR in Cancer 0.83 Signaling by FGFR in disease 0.91 DAP12 interactions 0.76 Signaling by ERBB2 0.89 Signaling by PDGF 0.72
2	PIP3 activates AKT signaling	8/10 pathways (see all 10) PIP3 activates AKT signaling 1.00 PI3K/AKT activation 0.97 PI3K/AKT Signaling in Cancer 1.00 GAB1 signalosome 0.96 PI3K events in ERBB2 signaling 1.00 Constitutive PI3K/AKT Signaling in Cancer 0.88 PI3K events in ERBB4 signaling 1.00 Signaling by SCF-KIT 0.72
3	GPCR Pathway	GPCR Pathway 1.00 Estrogen Pathway 0.55 Ras Pathway 0.62 Pancreatic Adenocarcinoma 0.55 Breast Cancer Regulation by Stathmin1 0.58 Paxillin Interactions 0.53 NFAT in Immune Response 0.58 P2Y Receptor Signaling 0.38
4	Development HGF signaling pathway	Development_EGFR signaling via small GTPases 0.44 Development_EGFR signaling via PIP3 0.26 Development EGFR signaling via small GTPases 0.44 Apoptosis and survival_Role of CDK5 in neuronal death and survival 0.24 Development EGFR signaling via PIP3 0.26 Apoptosis and survival Role of CDK5 in neuronal death and survival 0.24
5	Rho Family GTPases	Rho Family GTPases 1.00 MAPK Signaling 0.51 ERK Signaling 0.61 ILK Signaling 0.45 Molecular Mechanisms of Cancer 0.51

5/8 EMD Millipore Pathways for ERBB2

	Apoptosis and survival Role of CDK5 in neuronal death and survival
	Development EGFR signaling pathway
	Development TGF-beta receptor signaling
	Translation Non-genomic (rapid) action of Androgen Receptor
	Development Ligand-independent activation of ESR1 and ESR2

5/38 Downloadable PowerPoint Slides of QIAGEN Pathway Central Maps for ERBB2

	Paxillin Interactions
	Molecular Mechanisms of Cancer
	Intracellular Calcium Signaling
	JNK Pathway
	Tec Kinases Signaling

1 Cell Signaling Technology (CST) Pathway for ERBB2

Tyrosine Kinases / Adaptors

4 Tocris Bioscience Pathways for ERBB2

	Akt Pathway
	Apoptosis Pathway
	NF-kappaB Pathway
	MAPK Pathway

5/8 GeneGo (Thomson Reuters) Pathways for ERBB2

	Development ERBB-family signaling
	Development Ligand-independent activation of ESR1 and ESR2
	Apoptosis and survival Role of CDK5 in neuronal death and survival
	Development EGFR signaling via PIP3
	Development EGFR signaling pathway

5/15 BioSystems Pathways for ERBB2

	ErbB signaling pathway
	Signaling Pathways in Glioblastoma
	DNA damage response (only ATM dependent)
	Focal Adhesion
	Integrated Pancreatic Cancer Pathway

5/39        Reactome Pathways for ERBB2

	Signaling by EGFR in Cancer
	Downregulation of ERBB2:ERBB3 signaling
	Downstream signal transduction
	Signal Transduction
	Signaling by PDGF

1 PharmGKB Pathway for ERBB2

EGFR Inhibitor Pathway, Pharmacodynamics

5/10         Kegg Pathways  (Kegg details for ERBB2)

	ErbB signaling pathway
	Calcium signaling pathway
	Focal adhesion
	Adherens junction
	Pathways in cancer

Gene Ontology (GO): 5/49 biological process terms (GO ID links to tree view) (see all 49):    About this table

Drugs & Compounds
for ERBB2 gene

Transcripts
for ERBB2 gene

Expression
for ERBB2 gene

ERBB2 expression in normal human tissues (normalized intensities)
See probesets specificity/sensitivity at GeneAnnot
About this imageBioGPS
CGAP TAG: AGGAAGGAAC

10/17 LifeMap In Vivo Development Anatomical Compartments/Cells (see all 17)
	Tissue Anatomical Compartment Cell			Category (developmental path)
	HeartAtrioventricular Endocardial CushionEndocardial Cushion Cells			Endocardium
	HeartEndocardiumEndocardial Cells			Endocardium
	HeartLeft VentricleCardiomyocytes			Myocardium
	HeartRight VentricleCardiomyocytes			Myocardium
	Gut TubeMidgutMidgut Endoderm Cells			Endoderm
	BoneZeugopod Long Bone			Bone
	BrainCerebral Cortex			Brain
	BrainHypothalamus			Brain
	BrainMedulla Oblongata			Brain
	BrainThalamus			Brain
Expression: Positive    Negative     Selective marker Experimental details: Curated     Microarrays     In-situ hybridization

Primer Products:		OriGene genome-wide validated SYBR primer pairs in human, mouse, rat for ERBB2 Browse OriGene validated miRNA SYBR primer pairs
		SABiosciences RT2 qPCR Primer Assay in human, mouse, rat ERBB2
		QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat ERBB2
		QIAGEN QuantiFast Probe-based Assays in human, mouse, rat ERBB2

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for ERBB2

Orthologs
for ERBB2 gene

Paralogs
for ERBB2 gene

Paralogs for ERBB2 gene

SYK²  TNK1²  JAK2²  JAK3²  TNK2²  TYK2²  ERBB4²  JAK1²  

ERBB3²  PTK2²  ZAP70²  PTK2B²  EGFR²  

18/88 SIMAP similar genes for ERBB2 using alignment to 16 protein entries:     ERBB2_HUMAN (see all proteins) (see all similar genes):

WARS    HER-2    TNFRSF17    TSEN2    ZNF564    CRCP

EPHA4    APOD    FAM175A    HKR1    LOC100506792    NF2

UTY    CHID1    HMGA2    SHANK2    TMEM14B    FKBP3

ERBB2 for paralogs           About GeneDecksing

Genomic Variants
for ERBB2 gene

10/792 NCBI SNPs in ERBB2 are shown (see all 792)     About this table

Genomic Data					Transcription Related Data				Allele Frequencies
SNP ID	Valid	Clinical significance	Chr 17 pos	Sequence	#	AA Chg	Type	More	#	Allele freq	Pop	Total sample	More
-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	--	--	--	-1st2nd3rd	--	--	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd
rs11362011,2	C,F,H,	non-pathogenic	37432406(+)	CCATCA/G/TTCTCT	6	I V F	mis1		46		EA NS NA MN CSA EU	11776
rs18012011,2	C,F,	non-pathogenic	37432409(+)	CGTCCA/GTCATC	4	I V	mis1		9		MN NA EU	6283
rs289333681,2	C	other	37429998(+)	TGTGGG/AAGCTG	4	/K /E	mis1		2		NA	4
rs289333701,2	C,F	other	37430594(+)	TCCCAA/GCCATG	4	N S	mis1 ese3		2		NS NA	278
rs289333691,2	C	other	37430975(+)	TGGCTG/AGTGTG	4	/S /G	mis1 ese3		2		NA	4
rs753625181,2	C,	--	33637384(+)	GGCTGG/TGTGAC	1	--	us2k1		0	--	--	--	--
rs758499831,2	C,	--	33637687(+)	CATTCT/GCTGCC	1	--	us2k1		2		NA WA	120
rs563500741,2	C	--	33638264(+)	CGGAAG/ATTCCT	1	--	us2k1		1		WA	2
rs800858191,2	C,	--	33638320(+)	AAAGTC/TCCCGG	1	--	ut51		0	--	--	--	--
rs755828141,2	C,F,	--	33639026(+)	GAACAG/ACATAC	1	--	int1		1		WA	118

HapMap Linkage Disequilibrium report for ERBB2 (37844167 - 37886679 bp)
Structural Variations (Copy Number Variations, Insertions/Deletions, Inversions)
Database of Genomic Variants (DGV): 1 variation for ERBB2
     1 CNV: 77592
Human Gene Mutation Database (HGMD): ERBB2

5/21 SABiosciences Cancer Mutation PCR Assays for ERBB2 (see all 21): Cosmic Id AA Change 684 p.E914K 13170 p.D769H 48358 p.S310F 686 p.N857S 683 p.L755P

5/11 SABiosciences Cancer Mutation PCR Arrays containing ERBB2 (see all 11): ErbB2/HER2/neu Pathway Ovarian Cancer   Cancer Comprehensive Panel 384HT Lung Cancer Oncogene Panel 384HT

4 SABiosciences qBiomarker Copy Number PCR Arrays containing ERBB2: Oncogenes & Tumor Suppressor Genes 384HC Breast Cancer WNT Signaling Kinases & Phosphatases

QIAGEN SeqTarget long-range PCR primers in human, mouse, rat for resequencing ERBB2

DNA2.0 Custom Variant and Variant Library Synthesis for ERBB2

Disorders / Diseases
for ERBB2 gene

20/238 diseases for ERBB2

10/96 Novoseek disease relationships for ERBB2 gene (see all 96)    About this table

Publications
for ERBB2 gene

PubMed articles for ERBB2 gene, integrated from 9 sources (see all 4926) (see top 10): (articles sorted by number of sources associating them with ERBB2)

Utopia: connect your pdf to the dynamic world of online information

1. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. (PubMed id 12610629)^{1, 2, 9} Cho H.-S.... Leahy D.J. (2003)
2. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. (PubMed id 15126109)^{1, 4, 9} Akisik E. and Dalay N. (2004)
3. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. (PubMed id 19372587)^{1, 2, 9} Hawthorne V.S....Yu D. (2009)
4. EGFR and erbB2 mutation status in Japanese lung cancer patients. (PubMed id 16003726)^{1, 4, 9} Sasaki H....Fujii Y. (2006)
5. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. (PubMed id 16112085)^{1, 4, 9} Pinto D....Medeiros R. (2005)
6. Her2 genotype and breast cancer progression in Korean women. (PubMed id 15693849)^{1, 4, 9} An H.J....Lee K.S. (2005)
7. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. (PubMed id 15083213)^{1, 4, 9} Tayeb M.T....McLeod H.L. (2004)
8. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. (PubMed id 14520697)^{1, 4, 9} Kuraoka K....Yasui W. (2003)
9. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. (PubMed id 11857355)^{1, 4, 9} Wang L....Kato T. (2002)
10. Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility. (PubMed id 15389808)^{1, 4, 9} Yokomizo A....Naito S. (2005)
11. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. (PubMed id 15380516)^{1, 2, 9} Wang S.C....Hung M.C. (2004)
12. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. (PubMed id 14737100)^{1, 7, 9} Xia W....Spector N.L. (2004)
13. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. (PubMed id 14569185)^{1, 4, 9} Rutter J.L....Struewing J. (2003)
14. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. (PubMed id 12166652)^{1, 4, 9} Ameyaw M.M....McLead H.L. (2002)
15. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. (PubMed id 10805725)^{1, 2, 9} Arcaro A....Domin J. (2000)
16. Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes. (PubMed id 21555369)^{1, 2} Li L.Y.... Hung M.C. (2011)
17. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor , augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-dr iven cancer cell growth. (PubMed id 20658522)^{1, 7} Vazquez-Martin A....Menendez J.A. (2011)
18. Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signalin g pathways. (PubMed id 21190959)^{1, 2} Kharmate G....Kumar U. (2011)
19. Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein. (PubMed id 21454582)^{1, 2} Aertgeerts K.... Sogabe S. (2011)
20. ErbB2 receptor controls microtubule capture by recrui ting ACF7 to the plasma membrane of migrating cells. (PubMed id 20937854)^{1, 2} Zaoui K....Badache A. (2010)
21. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. (PubMed id 18719096)^{1, 2} Xiang B....Muthuswamy S.K. (2008)
22. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. (PubMed id 17081983)^{1, 2} Olsen J.V....Mann M. (2006)
23. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. (PubMed id 16794579)^{1, 2} Anido J....Arribas J. (2006)
24. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. (PubMed id 16000574)^{1, 4} Han W....Noh D.Y. (2005)
25. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. (PubMed id 15970791)^{1, 4} Cox D.G....Hunter D.J. (2005)
26. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. (PubMed id 15550452)^{1, 4} Frank B....Burwinkel B. (2005)
27. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. (PubMed id 15837541)^{1, 4} Kalemi T.G....Kotsis A. (2005)
28. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. (PubMed id 15754131)^{1, 4} Millikan R.C....Begg C.B. (2005)
29. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. (PubMed id 15987431)^{1, 4} Nelson S.E....Trentham-Dietz A. (2005)
30. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. (PubMed id 16314522)^{1, 2} Giri D.K....Hung M.C. (2005)
31. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. (PubMed id 15743501)^{1, 4} Benusiglio P.R....Ponder B.A. (2005)
32. Lung cancer: intragenic ERBB2 kinase mutations in tumours. (PubMed id 15457249)^{1, 2} Stephens P....Stratton M.R. (2004)
33. HER2 polymorphism and breast cancer risk in Portugal. (PubMed id 15167216)^{1, 4} Pinto D....Medeiros R. (2004)
34. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. (PubMed id 15210733)^{1, 2} Swiercz J.M.... Offermanns S. (2004)
35. Memo mediates ErbB2-driven cell motility. (PubMed id 15156151)^{1, 2} Marone R.... Badache A. (2004)
36. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. (PubMed id 15374636)^{1, 4} Kamali-Sarvestani E....Merat A. (2004)
37. Novel mode of ligand recognition by the Erbin PDZ domain. (PubMed id 12444095)^{1, 2} Birrane G.... Ladias J.A. (2003)
38. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. (PubMed id 12939402)^{1, 2} Li Y....Kufe D. (2003)
39. The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. (PubMed id 14578152)^{1, 4} Montgomery K.G....Campbell I.G. (2003)
40. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. (PubMed id 12846420)^{1, 4} Millikan R....Dressler L. (2003)
41. Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. (PubMed id 11578807)^{1, 4} Keshava C....Weston A. (2001)
42. Germ-line HER-2 variant and breast cancer risk by stage of disease. (PubMed id 11731415)^{1, 4} McKean-Cowdin R....Henderson B.E. (2001)
43. Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins. (PubMed id 11910656)^{1, 4} Bagger Y.Z....Christiansen C. (2000)
44. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. (PubMed id 11106692)^{1, 4} Ameyaw M.M....McLeod H.L. (2000)
45. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. (PubMed id 10593938)^{1, 2} Kuhns J.J.... Collins E.J. (1999)
46. Characterization of a new allele of the human ERBB2 gene by allele- specific competition hybridization. (PubMed id 8095488)^{1, 2} Ehsani A.... Wu A.M. (1993)
47. Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene. (PubMed id 8104414)^{1, 2} Sarkar F.H.... Crissman J.D. (1993)
48. Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. (PubMed id 3039351)^{1, 2} Tal M.... Givol D. (1987)
49. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. (PubMed id 3003577)^{1, 2} Yamamoto T.... Toyoshima K. (1986)
50. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c- erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. (PubMed id 2995967)^{1, 2} Semba K.... Yamamoto T. (1985)
51. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. (PubMed id 2999974)^{1, 2} Coussens L.... Ullrich A. (1985)
52. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. (PubMed id 2992089)^{1, 2} King C.R.... Aaronson S.A. (1985)
53. Association between HER2, TOP2A, and response to anth racycline-based preoperative chemotherapy in high-risk primary breast cancer. (PubMed id 20130985)^{1, 9} Konecny G.E....Slamon D.J. (2010)
54. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? (PubMed id 12209684)^{1, 9} Gandour-Edwards R....DeVere-White R. (2002)
55. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. (PubMed id 19728854)^{1, 9} SA...Brandslund I. (2009)
56. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. (PubMed id 19061514)^{1, 9} Liang Z....Liu T. (2008)
57. [Expression of HER2/neu in meningiomas: an immunohist ochemistry and fluorescence in situ hybridization study] (PubMed id 20450760)^{1, 9} Wang C.L....Xiong Y.F. (2010)
58. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. (PubMed id 14696118)^{1, 9} Half E....Sinicrope F.A. (2004)
59. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. (PubMed id 11071886)^{1, 9} Xu W....Neckers L. (2001)
60. Aberrations of ERBB2 and TOP2A genes in breast cancer . (PubMed id 19945923)^{1, 9} Nielsen K.V....Ejlertsen B. (2010)
61. Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype. (PubMed id 16538540)^{1, 9} Killeen J.L....Fu J.B. (2006)
62. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based co hort of patients with metastatic breast cancer. (PubMed id 20178580)^{1, 9} Toi M....Bates M. (2010)
63. Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease. (PubMed id 19409162)^{1, 9} Ahmad A....Khan A. (2009)
64. FoxM1 is a downstream target and marker of HER2 overe xpression in breast cancer. (PubMed id 19513552)^{1, 9} Francis R.E....Lam E.W. (2009)
65. Amplification of HER2 is a marker for global genomic instability. (PubMed id 18854030)^{1, 9} Ellsworth R.E....Shriver C.D. (2008)
66. Quercetin-induced ubiquitination and down-regulation of Her-2/neu. (PubMed id 18655187)^{1, 9} Jeong J.H....Lee Y.J. (2008)
67. Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. (PubMed id 17239458)^{1, 9} Jung Y....Neckers L. (2007)
68. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. (PubMed id 17555797)^{1, 9} Kim M.A....Kim W.H. (2007)
69. HER2 gene status in primary breast cancers and matched distant metastases. (PubMed id 17511881)^{1, 9} Tapia C....Bubendorf L. (2007)
70. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). (PubMed id 16075281)^{1, 9} Corte M.D....Vizoso F.J. (2005)
71. ErbB2 degradation mediated by the co-chaperone protein CHIP. (PubMed id 12574167)^{1, 9} Zhou P....Band H. (2003)
72. HER-2 and TOP2A coamplification in urinary bladder cancer. (PubMed id 14566826)^{1, 9} Simon R....Sauter G. (2003)
73. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. (PubMed id 12874758)^{1, 9} Nuciforo P.G....Bosari S. (2003)
74. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. (PubMed id 17211534)^{1, 9} Van Mieghem T....Neven P. (2007)
75. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. (PubMed id 17545611)^{1, 9} Magnifico A....Tagliabue E. (2007)
76. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. (PubMed id 17322545)^{1, 9} Kim H.J....Sohn J.H. (2007)
77. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1). (PubMed id 15190415)^{1, 9} Hermanova M....Dite P. (2004)
78. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. (PubMed id 19331129)^{1, 9} Ooi A....Dobashi Y. (2009)
79. Helicobacter pylori infection and expressions of EGF, EGFR and c-erbB-2 proteins in gastric carcinoma. (PubMed id 20164030)^{1, 9} Pryczynicz A....Czyzewska J. (2009)
80. HER-2, TOP2A and chromosome 17 alterations in breast cancer. (PubMed id 17922046)^{1, 9} Beser A.R....Dalay N. (2007)
81. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. (PubMed id 17575133)^{1, 9} Mounawar M....Hainaut P. (2007)
82. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. (PubMed id 17690040)^{1, 9} Zheng J. and Zhu Y.M. (2007)
83. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. (PubMed id 17992604)^{1, 9} Sakla M.S....Lubahn D.B. (2007)
84. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. (PubMed id 17549356)^{1, 9} Logullo A.F....Brentani M.M. (2007)
85. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. (PubMed id 15143334)^{1, 9} Ooi A....Dobashi Y. (2004)
86. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. (PubMed id 14680497)^{1, 9} Yamashita H....Iwase H. (2004)
87. Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. (PubMed id 20429940)^{1, 9} Bernardes V.F....Aguiar M.C. (2010)
88. Protein-tyrosine phosphatase PTPN9 negatively regulat es ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. (PubMed id 20335174)^{1, 9} Yuan T....Gu H. (2010)
89. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. (PubMed id 20068093)^{1, 9} Petry I.B....Hengstler J.G. (2010)
90. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. (PubMed id 19156142)^{1, 9} Barros-Silva J.D....Teixeira M.R. (2009)
91. Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach. (PubMed id 20430735)^{1, 9} Czyzewska J....Kemona A. (2009)
92. Her-2/neu, p-53, and their coexpression in osteosarcoma. (PubMed id 19346874)^{1, 9} Bakhshi S....Rastogi S. (2009)
93. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. (PubMed id 18067636)^{1, 9} Cho E.Y....Oh Y.L. (2008)
94. EGFR, HER-2 and COX-2 levels in colorectal cancer. (PubMed id 19102009)^{1, 9} Antonacopoulou A.G....Kalofonos H.P. (2008)
95. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. (PubMed id 17636399)^{1, 9} Ryden L....Bendahl P.O. (2008)
96. The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population. (PubMed id 19055823)^{1, 9} Jo U.H....Kim Y.H. (2008)
97. [Correlations of HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast cancer] (PubMed id 17626754)^{1, 9} Yang L....Ran L. (2007)
98. Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population. (PubMed id 17644807)^{1, 9} Kitao K....Maruo T. (2007)
99. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. (PubMed id 17321325)^{1, 9} Bae N.C....Park J.Y. (2007)
100. Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. (PubMed id 17431415)^{1, 9} Mitsui F....Ooi A. (2007)
101. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. (PubMed id 16686942)^{1, 9} Chaube A....Shukla H.S. (2006)
102. TOP2A and HER2 gene amplification as predictors of re sponse to anthracycline treatment in breast cancer. (PubMed id 16864174)^{1, 9} Villman K....Blomqvist C. (2006)
103. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. (PubMed id 16847810)^{1, 9} Fijol/ek J....Roszkowski K. (2006)
104. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. (PubMed id 15572377)^{1, 9} Hendriks B.S....Lauffenburger D.A. (2005)
105. Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells. (PubMed id 15757908)^{1, 9} Kuwada S.K....Li X. (2005)
106. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. (PubMed id 15688416)^{1, 9} Provinciali M....Smorlesi A. (2005)
107. Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2. (PubMed id 14711810)^{1, 9} Tikhomirov O. and Carpenter G. (2004)
108. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. (PubMed id 15014023)^{1, 9} Konecny G.E....Pegram M.D. (2004)
109. Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. (PubMed id 12888923)^{1, 9} Huynh H....Tran E. (2003)
110. Enhanced expression of the UROC28 gene in human breast cancer: relationship to ERBB2 gene expression. (PubMed id 12553037)^{1, 9} Kamagata C....Watanabe N. (2002)
111. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. (PubMed id 11786427)^{1, 9} Savinainen K.J....Visakorpi T. (2002)
112. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. (PubMed id 11972392)^{1, 9} Ferrandina G....Scambia G. (2002)
113. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. (PubMed id 10829039)^{1, 9} Allgayer H....Heiss M.M. (2000)
114. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. (PubMed id 7556068)^{1, 9} Wallasch C....Ullrich A. (1995)
115. Her4 and Her2/neu tyrosine kinase domains dimerize an d activate in a reconstituted in vitro system. (PubMed id 20022944)^{1, 9} Monsey J....Bose R. (2010)
116. Inhibition of non-small cell lung cancer cell prolife ration and tumor growth by vector-based small interfering RNAs targeting HER2/n eu. (PubMed id 19339104)^{1, 9} Ren X.L....Yang A.G. (2009)
117. Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17. (PubMed id 19443884)^{1, 9} Simonetti S....Insabato L. (2009)
118. Factors associated with HER2 overexpression in breast cancer: Experience in an Asian developing country. (PubMed id 20104975)^{1, 9} Tan G.H....Yip C.H. (2009)
119. [Correlation analysis of vascular endothelial growth factor-C expression and clinicopathology in breast cancer.] (PubMed id 19923084)^{1, 9} Fu J.M....Zhou J. (2009)
120. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. (PubMed id 19060928)^{1, 9} Scaltriti M....Baselga J. (2009)
121. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. (PubMed id 19208313)^{1, 9} Sharif M.A....Khadim M.T. (2009)
122. The influence of HER2 genotypes as molecular markers on breast cancer outcome. (PubMed id 18721072)^{1, 9} Mutluhan H....Seyrek E. (2008)
123. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. (PubMed id 18769124)^{1, 9} Raja S.M....Band H. (2008)
124. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. (PubMed id 18237245)^{1, 9} Naidu R....Taib N.A. (2008)
125. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. (PubMed id 18237248)^{1, 9} Papadopoulou E....Kortsaris A. (2008)
126. Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy. (PubMed id 18645672)^{1, 9} Dai B....Yao X.D. (2008)
127. Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. (PubMed id 19034345)^{1, 9} Ismail H.M....Touny A. (2007)
128. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. (PubMed id 17975153)^{1, 9} Arnould L....Coudert B.P. (2007)
129. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. (PubMed id 17487844)^{1, 9} Soh J....Date H. (2007)
130. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations. (PubMed id 17453369)^{1, 9} Hagen A.I....Lonning P.E. (2007)
131. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. (PubMed id 17221157)^{1, 9} Ozcelik H....Andrulis I.L. (2007)
132. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. (PubMed id 17549377)^{1, 9} Brys M....Krajewska W.M. (2007)
133. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. (PubMed id 16169726)^{1, 9} Cho M.H....Min K.W. (2006)
134. [Correlation between the expression of HER-2/neu, nm23 protein and local invasion and lymph node metastasis of human LSCC] (PubMed id 16739379)^{1, 9} Li Q....Zhang D. (2006)
135. Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients. (PubMed id 15735564)^{1, 9} Tavangar S.M....Soroush A.R. (2005)
136. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. (PubMed id 14719098)^{1, 9} Essapen S....Modjtahedi H. (2004)
137. [Expression of bcl-2, c-erbB2, and p53 protein in cer vical epithelial carcinogenesis] (PubMed id 14558950)^{1, 9} Tang Z.H....Ye X.A. (2003)
138. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. (PubMed id 11895493)^{1, 9} Aishima S.I....Tsuneyoshi M. (2002)
139. Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. (PubMed id 12419588)^{1, 9} Fernandez Val J.F....Sarria R. (2002)
140. Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder. (PubMed id 12474525)^{1, 9} Morgan B.E....Morgan M.B. (2002)
141. Genetic and expression analysis of HER-2 and EGFR gen es in salivary duct carcinoma: empirical and therapeutic significance. (PubMed id 20371674)^{1, 9} Williams M.D....El-Naggar A.K. (2010)
142. Immunohistochemical detection of phospho-Akt, phospho -BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer pa tients. (PubMed id 19882362)^{1, 9} Seow H.F....Rohaizak M. (2010)
143. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. (PubMed id 19255333)^{1, 9} Leary A.F....Dowsett M. (2009)
144. HER2 overexpression correlates with survival after cu rative resection of pancreatic cancer. (PubMed id 19432892)^{1, 9} Komoto M....Hirakawa K. (2009)
145. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. (PubMed id 19401546)^{1, 9} O'Malley F.P....Pritchard K.I. (2009)
146. The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma. (PubMed id 18427947)^{1, 9} He Q....Wang X.L. (2009)
147. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. (PubMed id 19360341)^{1, 9} Wong L.L....Zhang D. (2009)
148. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab the rapy. (PubMed id 20003286)^{1, 9} McAlpine J.N....Miller D.M. (2009)
149. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast ca ncer cells. (PubMed id 18807177)^{1, 9} Sengupta S....Katzenellenbogen B.S. (2009)
150. Study of inhibition effect of herceptin on interactio n between heregulin and erbB receptors HER3/HER2 by single-molecule force spect roscopy. (PubMed id 19497323)^{1, 9} Shi X....Fang X. (2009)
151. Useful immunohistochemical markers for distinguishing Paget cells from Toker cells. (PubMed id 20001343)^{1, 9} Park S. and Suh Y.L. (2009)
152. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trast uzumab-resistant breast cancer. (PubMed id 19509242)^{1, 9} Dokmanovic M....Wu W.J. (2009)
153. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. (PubMed id 18628098)^{1, 9} Hansel D.E....Tubbs R.R. (2008)
154. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. (PubMed id 18409049)^{1, 9} Yang J.W....Kang K.W. (2008)
155. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. (PubMed id 18337451)^{1, 9} Chinni S.R....Cher M.L. (2008)
156. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. (PubMed id 18199554)^{1, 9} Gilmer T.M....Wood E.R. (2008)
157. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. (PubMed id 18316615)^{1, 9} Fujii T....Kage M. (2008)
158. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. (PubMed id 18337455)^{1, 9} Pedersen N.M....Stang E. (2008)
159. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. (PubMed id 18463983)^{1, 9} Sharif S....Krasinskas A.M. (2008)
160. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. (PubMed id 18415713)^{1, 9} Caner V....Duzcan S.E. (2008)
161. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. (PubMed id 17361205)^{1, 9} Tapia C....Sauter G. (2007)
162. Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. (PubMed id 18038879)^{1, 9} Fantinato A.P....del Giglio A. (2007)
163. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. (PubMed id 17693647)^{1, 9} Beauclair S....Milano G. (2007)
164. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. (PubMed id 16947041)^{1, 9} Park D.I....Sepulveda A.R. (2007)
165. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. (PubMed id 17102066)^{1, 9} Gabos Z....Abdulkarim B. (2006)
166. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. (PubMed id 16984552)^{1, 9} Okegawa T....Higashihara E. (2006)
167. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. (PubMed id 16685109)^{1, 9} Tsiambas E....Patsouris E. (2006)
168. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. (PubMed id 15917726)^{1, 9} Bozcuk H....Savas B. (2005)
169. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. (PubMed id 16168116)^{1, 9} Kim A....Thor A.D. (2005)
170. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. (PubMed id 15756435)^{1, 9} Shimada M....Kawaguchi R. (2005)
171. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. (PubMed id 16000588)^{1, 9} Mimura K....Fujii H. (2005)
172. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. (PubMed id 15632176)^{1, 9} Ghatak S....Toole B.P. (2005)
173. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. (PubMed id 15173068)^{1, 9} Yang Z....Kumar R. (2004)
174. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (PubMed id 15093539)^{2, 9} Franklin M.C....Sliwkowski M.X. (2004)
175. Her-2 expression in cutaneous eccrine and apocrine neoplasms. (PubMed id 14631375)^{1, 9} Hiatt K.M....Smoller B.R. (2004)
176. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. (PubMed id 14634801)^{1, 9} Potti A....Kargas S. (2004)
177. Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells. (PubMed id 15520177)^{1, 9} Kim S.W....Lee J.D. (2004)
178. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. (PubMed id 14751502)^{7, 9} Zhou H....Sartor C.I. (2004)
179. Role of proliferation in HER2 status predicted response to doxorubicin. (PubMed id 12712452)^{1, 9} Campiglio M....Menard S. (2003)
180. The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. (PubMed id 12867284)^{1, 9} Hou M.F....Tsai L.Y. (2003)
181. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. (PubMed id 12544770)^{1, 9} Zhou H....Goldsby R.E. (2003)
182. Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. (PubMed id 12883692)^{1, 9} Yokoi A....Kandel J.J. (2003)
183. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. (PubMed id 1351056)^{1, 9} Peles E....Yarden Y. (1992)
184. The role of oestrogen receptor {alpha} in human thyro id cancer: contributions from coregulatory proteins and the tyrosine kinase rec eptor HER2. (PubMed id 20032008)^{1, 9} Kavanagh D.O....Young L.S. (2010)
185. Increase of the therapeutic effect by treating nasoph aryngeal tumor with combination of HER-2 siRNA and paclitaxel. (PubMed id 20198351)^{1, 9} Hattori Y....Maitani Y. (2010)
186. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?] (PubMed id 20443098)^{1, 9} RA1schoff J....Kreipe H.H. (2010)
187. Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours. (PubMed id 20204273)^{1, 9} Srirajaskanthan R....Caplin M.E. (2010)
188. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. (PubMed id 19887485)^{1, 9} Roepman P....van de Vijver M.J. (2009)
189. TOB1 is regulated by EGF-dependent HER2 and EGFR sign aling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. (PubMed id 19491269)^{1, 9} Helms M.W....Brandt B.H. (2009)
190. HER-2 amplification is highly homogenous in gastric cancer. (PubMed id 19269014)^{1, 9} Marx A.H....Sauter G. (2009)
191. The effect of HER2 expression on cisplatin-based chem otherapy in advanced non-small cell lung cancer patients. (PubMed id 19575783)^{1, 9} Calikusu Z....Ozyilkan O. (2009)
192. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. (PubMed id 19299620)^{2, 9} Bostrom J....Fuh G. (2009)
193. HER-2 overexpression/amplification in Barrett's oesop hagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pat hologic study. (PubMed id 19292734)^{1, 9} Rossi E....Bassotti G. (2009)
194. MUC4 involvement in ErbB2/ErbB3 phosphorylation and signaling in response to airway cell mechanical injury. (PubMed id 19288496)^{1, 9} Theodoropoulos G....Carraway K.L. (2009)
195. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. (PubMed id 19292937)^{1, 9} Hsu H.C....Shen W.C. (2009)
196. Antitumor effect in medulloblastoma cells by gefitini b: Ectopic HER2 overexpression enhances gefitinib effects in vivo. (PubMed id 19033425)^{1, 9} Meco D....Riccardi R. (2009)
197. HER2 overexpression and activation, and tamoxifen eff icacy in receptor-positive early breast cancer. (PubMed id 19034514)^{1, 9} Singer C.F....Kubista E. (2009)
198. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin. (PubMed id 18078328)^{1, 9} Liang C.H....Kuo K.W. (2008)
199. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. (PubMed id 18700025)^{1, 9} Shen L....Wei Q. (2008)
200. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. (PubMed id 18296077)^{1, 9} Hussein M.R....Abdulwahed A.R. (2008)
201. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. (PubMed id 17468948)^{1, 9} Andre F....Pusztai L. (2008)
202. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. (PubMed id 18097576)^{1, 9} Matsubara H....Honda N. (2008)
203. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. (PubMed id 18700973)^{1, 9} Young C.D....Anderson S.M. (2008)
204. Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas. (PubMed id 19061288)^{1, 9} DeRoche T.C....Hunt J.L. (2008)
205. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. (PubMed id 18189290)^{1, 9} Brown M....Caggiano V. (2008)
206. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. (PubMed id 18324648)^{1, 9} Ricciardelli C....Tilley W.D. (2008)
207. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. (PubMed id 18208799)^{1, 9} Sartori G....Rossi G. (2008)
208. [Correlations of c-erb-B2, EGFR, and TGF-alpha expression to recurrence of Dukes'A and B colorectal carcinoma] (PubMed id 17562274)^{1, 9} Liang J.L....Zhou Z.W. (2007)
209. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. (PubMed id 17626639)^{1, 9} Pugh T.J....Marra M.A. (2007)
210. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. (PubMed id 17671674)^{1, 9} Wei Q....Carlsson J. (2007)
211. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. (PubMed id 16978839)^{2, 9} Li Z....Zhou M. (2007)
212. [Protein overexpression and gene copy number of EGFR and HER2 in colorectal carcinoma] (PubMed id 17845756)^{1, 9} Zeng X....Liu T.H. (2007)
213. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. (PubMed id 17487843)^{1, 9} Sherman M.E....Garcia-Closas M. (2007)
214. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. (PubMed id 17622245)^{1, 9} Kawaguchi Y....Fujii H. (2007)
215. Glassy cell carcinoma of the cervix: cytologic features and expression of estrogen receptor, progesterone receptor and Her2/neu protein. (PubMed id 16901007)^{1, 9} Kuroda H....Itoyama S. (2006)
216. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. (PubMed id 16609045)^{1, 9} Merrick D.T....Hirsch F.R. (2006)
217. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. (PubMed id 16799708)^{1, 9} Sughayer M.A....Al-Masri M. (2006)
218. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. (PubMed id 16761619)^{1, 9} Potemski P....Kordek R. (2006)
219. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. (PubMed id 17079488)^{1, 9} Meng S....Uhr J. (2006)
220. HER-2/neu amplification is an independent prognostic factor in gastric cancer. (PubMed id 16868827)^{1, 9} Park D.I....Sepulveda A.R. (2006)
221. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. (PubMed id 16627988)^{1, 9} Liu X....Friedman S.M. (2006)
222. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. (PubMed id 15862947)^{1, 9} St-Laurent V....Tremblay A. (2005)
223. Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. (PubMed id 14660651)^{1, 9} Gensler M....Ullrich A. (2004)
224. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. (PubMed id 15447984)^{1, 9} Gregorc V....Villa E. (2004)
225. HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA. (PubMed id 15137060)^{1, 9} Galmozzi E....Menard S. (2004)
226. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. (PubMed id 15026342)^{1, 9} Hughes D.P....McDonagh K.T. (2004)
227. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. (PubMed id 15542430)^{1, 9} Li Y.M....Hung M.C. (2004)
228. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. (PubMed id 12820337)^{1, 9} Luftner D....Possinger K. (2003)
229. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. (PubMed id 14555515)^{1, 9} Jensen B.V....Price P.A. (2003)
230. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. (PubMed id 14647146)^{1, 9} Schlieman M.G....Bold R.J. (2003)
231. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. (PubMed id 12560434)^{1, 9} Love R.R....Allred D.C. (2003)
232. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. (PubMed id 12607595)^{1, 9} Lee J.S....Park C.S. (2002)
233. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. (PubMed id 11759828)^{1, 9} Konecny G....Pegram M. (2001)
234. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. (PubMed id 11067847)^{1, 9} Zhang X.Q....Lin M.F. (2001)
235. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. (PubMed id 11751413)^{1, 9} Moulder S.L....Arteaga C.L. (2001)
236. Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in schwann cells. (PubMed id 10799311)^{1, 9} Vartanian T....Fischbach G. (2000)
237. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. (PubMed id 10851066)^{1, 9} Meng T.C....Lin M.F. (2000)
238. Unique carboxyl-terminal sequences of wild type and alternatively spliced variant forms of transforming growth factor-alpha precursors mediate specific interactions with ErbB4 and ErbB2. (PubMed id 10918572)^{1, 9} Xu X....Pirisi L. (2000)
239. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. (PubMed id 10485918)^{1, 9} Doherty J.K.... Clinton G.M. (1999)
240. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. (PubMed id 7592681)^{1, 9} Horan T....Philo J.S. (1995)
241. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. (PubMed id 7514177)^{1, 9} Sliwkowski M.X....Carraway K.L. (1994)
242. Synergistic antitumor effect of S-1 and HER2-targetin g agents in gastric cancer with HER2 amplification. (PubMed id 20424000)^{1, 9} Tanizaki J....Nakagawa K. (2010)
243. Capsaicin causes cell-cycle arrest and apoptosis in E R-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathw ay. (PubMed id 19855437)^{1, 9} Thoennissen N.H....Koeffler H.P. (2010)
244. Molecular subtype can predict the response and outcom e of Chinese locally advanced breast cancer patients treated with preoperative therapy. (PubMed id 20372832)^{1, 9} Chen X.S....Shen K.W. (2010)
245. Gangliosides influence EGFR/ErbB2 heterodimer stabili ty but they do not modify EGF-dependent ErbB2 phosphorylation. (PubMed id 20156584)^{1, 9} Milani S....Colombo I. (2010)
246. ErbB-2 expression and its association with other biol ogical parameters of breast cancer among Indian women. (PubMed id 20071783)^{1, 9} Vaidyanathan K....Mukherjee G. (2010)
247. HER2 expression in gastric cancer: Rare, heterogeneou s and of no prognostic value - conclusions from 924 cases of two independent se ries. (PubMed id 20208134)^{1, 9} Grabsch H....MA1ller W. (2010)
248. Resistance to ErbB2 tyrosine kinase inhibitors in bre ast cancer is mediated by calcium-dependent activation of RelA. (PubMed id 20124457)^{1, 9} Xia W....Spector N.L. (2010)
249. Co-expression of survivin, c-erbB2, and cyclooxygenas e-2 (COX-2): prognostic value and survival of endometrial cancer patients. (PubMed id 19756737)^{1, 9} Lambropoulou M....Chatzaki E. (2010)
250. [Correlation of epidermal growth factor receptor muta tions and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib] (PubMed id 20038315)^{1, 9} Han Y....Zhang J.S. (2010)
251. Lapatinib restores hormone sensitivity with different ial effects on estrogen receptor signaling in cell models of human epidermal gr owth factor receptor 2-negative breast cancer with acquired endocrine resistanc e. (PubMed id 20179226)^{1, 9} Leary A.F....Johnston S.R. (2010)
252. Overexpression of c-erbB2 is a negative prognostic fa ctor in anaplastic astrocytomas. (PubMed id 20331873)^{1, 9} Gulati S....Torp S.H. (2010)
253. Upregulation of lactate dehydrogenase A by ErbB2 thro ugh heat shock factor 1 promotes breast cancer cell glycolysis and growth. (PubMed id 19668225)^{1, 9} Zhao Y.H....Tan M. (2009)
254. The involvement of HER2 and p53 status in the regulat ion of telomerase in irradiated breast cancer cells. (PubMed id 19787269)^{1, 9} Papanikolaou V....Tsezou A. (2009)
255. [Association between HRE-2 gene polymorphism at codon 655 and genetic susceptibility of colorectal cancer] (PubMed id 19504444)^{1, 9} Liang X....Chen K. (2009)
256. Prognostic impact of HER2/neu protein in urothelial b ladder cancer. Survival analysis of 80 cases and an overview of almost 20 years ' research. (PubMed id 19810139)^{1, 9} Skagias L....Patsouris E. (2009)
257. Induction of ERBB2 nuclear transport after radiation in breast cancer cells. (PubMed id 19513620)^{1, 9} Luo B....Rong L. (2009)
258. HER2 expression in breast cancer: correlation with en docrine function and psychological status in operable and metastatic breast can cer. (PubMed id 20023245)^{1, 9} Lissoni P....Bartolacelli E. (2009)
259. Suppression of ErbB-2 in androgen-independent human p rostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-re duced environment. (PubMed id 19467571)^{1, 9} Zhang L....Lin M.F. (2009)
260. Her-2/neu gene amplification in paraffin-embedded tis sue sections of meningioma patients. (PubMed id 19431122)^{1, 9} Ozer O....AltinAPrs N. (2009)
261. Analysis of ErbB receptors in pulmonary carcinoid tumors. (PubMed id 19447869)^{1, 9} Rickman O.B....Thomas C.F. (2009)
262. Outcome of patients with early-stage breast cancer tr eated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TO P2A status. (PubMed id 19620488)^{1, 9} Tubbs R....Hayes D.F. (2009)
263. Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers. (PubMed id 19148499)^{1, 9} Haas S....BA1ttner R. (2009)
264. Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. (PubMed id 19093231)^{1, 9} Abdel Salam I....Abdel Wahab N. (2009)
265. 14-3-3zeta Cooperates with ErbB2 to promote ductal ca rcinoma in situ progression to invasive breast cancer by inducing epithelial-me senchymal transition. (PubMed id 19732720)^{1, 9} Lu J....Yu D. (2009)
266. Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. (PubMed id 18948375)^{1, 9} Singer C.F....Kubista E. (2009)
267. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site. (PubMed id 19263517)^{1, 9} Jansen S.M....van Leeuwen J.E. (2009)
268. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors. (PubMed id 18855148)^{1, 9} Papila C....Yanardag H. (2009)
269. Amplification and expression of EGFR and ERBB2 in Wil ms tumor. (PubMed id 19781441)^{1, 9} Vasei M....Sauter G. (2009)
270. EGFR and HER2 expression in advanced biliary tract ca ncer. (PubMed id 19777609)^{1, 9} Harder J....Opitz O.G. (2009)
271. Metastatic breast cancer survival according to HER2 a nd Topo2a gene status. (PubMed id 19729798)^{1, 9} TodoroviA8-RakoviA8 N....NikoliA8-VukosavljeviA8 D. (2009)
272. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. (PubMed id 18448999)^{1, 9} Kuyama S....Tanimoto M. (2008)
273. Immunophenotyping of serous carcinoma of the female genital tract. (PubMed id 18567994)^{1, 9} Nofech-Mozes S....Ghorab Z. (2008)
274. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. (PubMed id 17687649)^{1, 9} Neven P....Drijkoningen M. (2008)
275. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. (PubMed id 18258606)^{1, 9} Kim K.K....Lee J.H. (2008)
276. HER2/neu in systemic therapy for women with breast cancer: a systematic review. (PubMed id 17636396)^{1, 9} Dhesy-Thind B....Trudeau M. (2008)
277. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. (PubMed id 18592003)^{1, 9} Koletsa T....Kotoula V. (2008)
278. An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. (PubMed id 18364263)^{1, 9} Fong Y....Kao S.Y. (2008)
279. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. (PubMed id 18985033)^{1, 9} Koutras A.K....Fountzilas G. (2008)
280. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. (PubMed id 17982484)^{1, 9} Zhu J.H....Lee J.D. (2008)
281. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. (PubMed id 18808065)^{1, 9} Durand A....Fevre-Montange M. (2008)
282. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. (PubMed id 18056992)^{1, 9} Sidera K....Patsavoudi E. (2008)
283. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters? (PubMed id 18251938)^{1, 9} Angiero F....Sidoni A. (2008)
284. Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes. (PubMed id 18528705)^{1, 9} Silva S.D....Graner E. (2008)
285. [Correlation between lymph-node metastasis and combined expression of Hpa and C-erbB-2 of invasive ductal breast carcinoma] (PubMed id 18390199)^{1, 9} Zheng X.D....Mao D.H. (2008)
286. ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. (PubMed id 17563746)^{1, 9} Yuan T.C....Lin M.F. (2007)
287. Correlative expression of cyclooxygenase-1 (cox-1) and human epidermal growth factor receptor type-2 (her-2) in endometrial cancer. (PubMed id 18204294)^{1, 9} Sugimoto T....Nishimura R. (2007)
288. [Expression of C-erb B-2 and its relation to angiogen esis in nasopharyngeal carcinoma] (PubMed id 17959545)^{1, 9} Liu Y.M....Li H.G. (2007)
289. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. (PubMed id 18089823)^{1, 9} Engelman J.A....Janne P.A. (2007)
290. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (PubMed id 17473658)^{1, 9} Cappuzzo F....Varella-Garcia M. (2007)
291. In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. (PubMed id 17879632)^{1, 9} Layfield L.J. and Lewis C. (2007)
292. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. (PubMed id 17987577)^{1, 9} Jalali Nadoushan M.R....Zaeri F. (2007)
293. [Expressions and significances of EGFR, C-erbB2 and Ki-67 in nasal squamous cell carcinomas] (PubMed id 17674766)^{1, 9} Li J....Guo L. (2007)
294. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer. (PubMed id 17549338)^{1, 9} Yamada Y....Honda N. (2007)
295. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. (PubMed id 18087195)^{1, 9} Florena A.M....Franco V. (2007)
296. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. (PubMed id 17704139)^{1, 9} Qin H.R....Huebner K. (2007)
297. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. (PubMed id 16718853)^{1, 9} Satiroglu-Tufan N.L....Calli-Demirkan N. (2006)
298. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. (PubMed id 16682622)^{1, 9} Xia W....Spector N.L. (2006)
299. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. (PubMed id 16959370)^{1, 9} Sanchez-Ceja S.G....Gutierrez-Castellanos S. (2006)
300. HER 2/neu protein expression in colorectal cancer. (PubMed id 16681853)^{1, 9} Schuell B....Wrba F. (2006)
301. HER-2 status determination in breast carcinomas. A practical approach. (PubMed id 16372244)^{1, 9} Garcia-Caballero T....Fraga M. (2006)
302. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. (PubMed id 16894399)^{7, 9} Johnston S.R. and Leary A. (2006)
303. A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. (PubMed id 16782798)^{1, 9} Kumar N....Lauffenburger D.A. (2006)
304. Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. (PubMed id 16489645)^{1, 9} Prenzel K.L....Schneider P.M. (2006)
305. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. (PubMed id 16681686)^{1, 9} Park K....Shin E. (2006)
306. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. (PubMed id 16685269)^{1, 9} Memon A.A....Nexo E. (2006)
307. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. (PubMed id 15643424)^{1, 9} Xu W....Neckers L. (2005)
308. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. (PubMed id 15461591)^{1, 9} Fauquette V....Van Seuningen I. (2005)
309. Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site. (PubMed id 16184431)^{1, 9} Kamath S.A. and Buolamwini J.K. (2005)
310. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. (PubMed id 15722788)^{1, 9} Siziopikou K.P. and Khan S. (2005)
311. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. (PubMed id 15585632)^{1, 9} Giatromanolaki A....Sivridis E. (2004)
312. C-erb-B2 and Bcl-xl protein expression in Barrett's oesophagus in correlation with morphological parameters. (PubMed id 15638369)^{1, 9} Barwijuk-Machal/a M....Sobaniec-Lotowska M. (2004)
313. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. (PubMed id 14991576)^{1, 9} Varis A....Knuutila S. (2004)
314. Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2/neu and DNA ploidy in early cervical carcinoma: correlation with clinical outcome. (PubMed id 15201979)^{1, 9} Graflund M....Karlsson M.G. (2004)
315. Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. (PubMed id 15646832)^{1, 9} Vizoso F.J....Allende M.T. (2004)
316. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. (PubMed id 15217943)^{1, 9} Blackwell K.L....Harris L.N. (2004)
317. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. (PubMed id 12915878)^{4, 9} Chen I.H....Cheng A.J. (2003)
318. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. (PubMed id 12942124)^{1, 9} Vernimmen D....Winkler R. (2003)
319. Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: an immunohistochemical study. (PubMed id 14682475)^{1, 9} Gumurdulu D....Demircan O. (2003)
320. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. (PubMed id 14614020)^{1, 9} Junttila T.T....Elenius K. (2003)
321. [Expression of nm23 and c-erbB-2 proteins in cells of primary colorectal cancer and its metastases] (PubMed id 14664140)^{1, 9} Delektorskaia V.V....Kushlinskii N.E. (2003)
322. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1. (PubMed id 14689059)^{1, 9} Mrhalova M. and Kodet R. (2003)
323. Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer. (PubMed id 14566828)^{1, 9} Pollan M....Rojas J.M. (2003)
324. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. (PubMed id 11807823)^{1, 9} Vadlamudi R.K....Kumar R. (2002)
325. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. (PubMed id 12379776)^{1, 9} Glockner S....Kreipe H. (2002)
326. Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro. (PubMed id 12168050)^{1, 9} Castilleja A....Ioannides C.G. (2002)
327. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. (PubMed id 11850540)^{1, 9} Xu R....Feiner H. (2002)
328. Episomally mediated overexpression of wild-type erbB-2 transforms MCF-10A breast epithelial cells. (PubMed id 12462379)^{1, 9} Yu B.W....Ramachandran S. (2002)
329. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. (PubMed id 12438265)^{1, 9} DiGiovanna M.P....Stern D.F. (2002)
330. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. (PubMed id 12143054)^{1, 9} Endo K....Sirica A.E. (2002)
331. Anti-tumor activity of GW572016: a dual tyrosine kina se inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. (PubMed id 12214266)^{7, 9} Xia W....Spector N.L. (2002)
332. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. (PubMed id 11940572)^{1, 9} Ren Z. and Schaefer T.S. (2002)
333. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. (PubMed id 11245482)^{1, 9} Bonvini P....Neckers L.M. (2001)
334. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. (PubMed id 10358079)^{2, 9} Olayioye M.A....Hynes N.E. (1999)
335. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. (PubMed id 10085134)^{1, 9} Wong L....Johnson G.R. (1999)
336. Studies on the betacellulin receptor in pancreatic AR42J cells. (PubMed id 9662041)^{1, 9} Ishiyama N....Kojima I. (1998)
337. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. (PubMed id 8617772)^{1, 9} Chavany C....Neckers L. (1996)
338. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. (PubMed id 7538656)^{1, 9} Alimandi M....Kraus M.H. (1995)
339. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. (PubMed id 1676673)^{1, 9} Peles E....Yarden Y. (1991)
340. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcin oembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma . (PubMed id 20350214)^{1, 9} Huang W.W....Tseng C.E. (2010)
341. Evaluation of tumor markers (HER-2/neu oncoprotein, C EA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. (PubMed id 20361287)^{1, 9} Molina R....Velasco M. (2010)
342. Detection and HER2 expression of circulating tumor ce lls: prospective monitoring in breast cancer patients treated in the neoadjuvan t GeparQuattro trial. (PubMed id 20406831)^{1, 9} Riethdorf S....Pantel K. (2010)
343. Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. (PubMed id 20014947)^{1, 9} Ali M.A....Nagatsuka H. (2010)
344. Assessing HER2 gene amplification as a potential targ et for therapy in invasive urothelial bladder cancer with a standardized method ology: results in 1005 patients. (PubMed id 19889613)^{1, 9} LaAc M....Vieillefond A. (2010)
345. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma] (PubMed id 20038314)^{1, 9} Song Y....Wang J.W. (2010)
346. Interaction of syndecan and alpha6beta4 integrin cyto plasmic domains: regulation of ErbB2-mediated integrin activation. (PubMed id 20181947)^{1, 9} Wang H....Rapraeger A.C. (2010)
347. HER2 codon 655 polymorphism is associated with advanc ed uterine cervical carcinoma. (PubMed id 20026098)^{1, 9} Kruszyna A.8....JagodziA8ski P.P. (2010)
348. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcino mas of the biliary tree and gallbladder. (PubMed id 20040392)^{1, 9} Shafizadeh N....Kakar S. (2010)
349. Steroid receptors, HER2/neu and Ki-67, in endometrioi d type of endometrial carcinoma: Correlation with conventional histomorphologic al features of prognosis. (PubMed id 19446313)^{1, 9} Chakravarty D....Dhaliwal L. (2010)
350. Shc is required for ErbB2-induced inhibition of apopt osis but is dispensable for cell proliferation and disruption of cell polarity. (PubMed id 19826412)^{1, 9} Lucs A.V....Muthuswamy S.K. (2010)
351. Expression of p53, c-erbB-2 and Ki67 in intestinal me taplasia and gastric carcinoma. (PubMed id 20082479)^{1, 9} Zheng Y....Zhang X.Y. (2010)
352. Overexpression of Grb2/HER2 signaling in Chinese gast ric cancer: their relationship with clinicopathological parameters and prognost ic significance. (PubMed id 19337752)^{1, 9} Yu G.Z....Wang J.J. (2009)
353. Serum tumor necrosis factor-alpha and interleukin-2 c oncentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patien ts. (PubMed id 19787624)^{1, 9} Saglam S....Gurdol F. (2009)
354. HER-2/neu and topoisomerase-II-alpha expression and g enic amplification in pancreatic adenocarcinoma. (PubMed id 19582575)^{1, 9} Baiocchi G.L....Giulini S.M. (2009)
355. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non -small cell lung cancer. (PubMed id 19648825)^{1, 9} Kashihara M....Ono M. (2009)
356. HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. (PubMed id 19519604)^{1, 9} Plaza J.A....Prieto V.G. (2009)
357. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. (PubMed id 19491261)^{1, 9} Cai C....Balk S.P. (2009)
358. Involvement of the HER2 pathway in repair of DNA dama ge produced by chemotherapeutic agents. (PubMed id 19887555)^{1, 9} Boone J.J....Hochhauser D. (2009)
359. HER2/neu (c-erbB-2) gene amplification and protein ex pression are rare in uterine cervical neoplasia: a tissue microarray study of 8 14 archival specimens. (PubMed id 19775342)^{1, 9} Lesnikova I....Koch J. (2009)
360. Lack of elevated HER2/neu expression in epithelial dy splasia and oral squamous cell carcinoma in Iran. (PubMed id 19827890)^{1, 9} Seifi S....Ariaeifar B. (2009)
361. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. (PubMed id 19128465)^{1, 9} Sato-Kuwabara Y....Soares F.A. (2009)
362. miR-331-3p regulates ERBB-2 expression and androgen r eceptor signaling in prostate cancer. (PubMed id 19584056)^{1, 9} Epis M.R....Leedman P.J. (2009)
363. Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. (PubMed id 19058300)^{1, 9} Gratio V....Darmoul D. (2009)
364. Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. (PubMed id 19208263)^{1, 9} Ha S.A....Kim J.W. (2009)
365. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. (PubMed id 19610068)^{1, 9} Liu J....Feitelson M.A. (2009)
366. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. (PubMed id 19294521)^{1, 9} Bratland A....Ree A.H. (2009)
367. Human epidermal growth factor receptor 2-positive bre ast cancer and central nervous system metastases. (PubMed id 19770385)^{1, 9} Leyland-Jones B. (2009)
368. Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. (PubMed id 19294416)^{1, 9} Uzan C....Vielh P. (2009)
369. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhib itor, downregulates thymidylate synthase by inhibiting the nuclear translocatio n of EGFR and HER2. (PubMed id 19529774)^{1, 9} Kim H.P....Kim T.Y. (2009)
370. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. (PubMed id 19318561)^{1, 9} Pignon J.C....Winkler R. (2009)
371. HER family receptor abnormalities in lung cancer brai n metastases and corresponding primary tumors. (PubMed id 19622585)^{1, 9} Sun M....Wistuba I.I. (2009)
372. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. (PubMed id 19252432)^{1, 9} Gilcrease M.Z....Buchholz T.A. (2009)
373. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. (PubMed id 18437556)^{1, 9} Bramwell V.H....Chambers A.F. (2009)
374. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (PubMed id 18632642)^{1, 9} Lee-Hoeflich S.T....Stern H.M. (2008)
375. Clinical pharmacology of trastuzumab. (PubMed id 18690878)^{7, 9} LevA-que D....Bergerat J.P. (2008)
376. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. (PubMed id 18650488)^{1, 9} Holtkamp N....von Deimling A. (2008)
377. Molecular markers (c-erbB-2, p53) in breast cancer. (PubMed id 19141397)^{1, 9} Agrawal A.K....Nienartowicz E. (2008)
378. Prognostic significance of HER2 gene amplification according to stage of breast cancer. (PubMed id 18583876)^{1, 9} Kim Y.S....Park W.C. (2008)
379. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. (PubMed id 19077306)^{1, 9} Lam P.B....Wulf G.M. (2008)
380. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. (PubMed id 18174256)^{1, 9} Ou C.C....Kao M.C. (2008)
381. The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11. (PubMed id 18724389)^{1, 9} Chen C.... Seth A.K. (2008)
382. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells. (PubMed id 19010824)^{1, 9} Warrenfeltz S.W....Puett D. (2008)
383. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. (PubMed id 18397823)^{1, 9} Miyahara N....Irimura T. (2008)
384. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. (PubMed id 18768436)^{1, 9} Bartlett J.M....Twelves C.J. (2008)
385. The Val allele of HER-2 codon 655 predicts the progression of oral squamous cell carcinoma. (PubMed id 18849186)^{1, 9} Wu C.H....Kao S.Y. (2008)
386. Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. (PubMed id 18509272)^{1, 9} Micozkadioglu D....Cinel L. (2008)
387. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. (PubMed id 18684832)^{1, 9} Menotti L....Campadelli-Fiume G. (2008)
388. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. (PubMed id 18516291)^{1, 9} Naderi A. and Hughes-Davies L. (2008)
389. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. (PubMed id 18469157)^{1, 9} Dillon M.F....Young L.S. (2008)
390. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. (PubMed id 18483367)^{1, 9} Matsubara J....Shimoda T. (2008)
391. Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. (PubMed id 18425397)^{1, 9} Beeghly-Fadiel A....Zheng W. (2008)
392. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. (PubMed id 18408761)^{1, 9} Li D....Wong K.K. (2008)
393. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. (PubMed id 18803986)^{7, 9} Medina P.J. and Goodin S. (2008)
394. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. (PubMed id 17451461)^{1, 9} Odicino F.E....Pecorelli S. (2008)
395. Molecular characterisation of breast cancer patients at high and low recurrence risk. (PubMed id 18236071)^{1, 9} Bonin S....Stanta G. (2008)
396. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. (PubMed id 18202752)^{1, 9} Engelsen I.B....Salvesen H.B. (2008)
397. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. (PubMed id 18248390)^{1, 9} Singh P....Davy M.L. (2008)
398. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. (PubMed id 18381409)^{1, 9} Chaturvedi P....Batra S.K. (2008)
399. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions. (PubMed id 18801081)^{1, 9} Kunju L.P....Kleer C.G. (2008)
400. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors] (PubMed id 19192581)^{1, 9} Hurkens K.P....Tjan-Heijnen V.C. (2008)
401. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. (PubMed id 18172732)^{1, 9} Wei Q....Carlsson J. (2008)
402. Could the truncated variant of ERBB2 be present in the squamous carcinomas of the cervix? (PubMed id 18818943)^{1, 9} Costa C....Alameda F. (2008)
403. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? (PubMed id 17262082)^{1, 9} Vincent-Salomon A....Sastre-Garau X. (2007)
404. [Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers] (PubMed id 18159174)^{1, 9} Joo H.H....Choi Y.K. (2007)
405. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. (PubMed id 17571214)^{1, 9} Mineo J.F....Dam Hieu P. (2007)
406. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. (PubMed id 17440164)^{1, 9} Scaltriti M....Baselga J. (2007)
407. Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. (PubMed id 17374991)^{1, 9} Bianchi F....Campiglio M. (2007)
408. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients. (PubMed id 20306655)^{1, 9} Zeiwar M.M....El Nagar M.R. (2007)
409. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. (PubMed id 17541441)^{1, 9} Gaedcke J....Kreipe H.H. (2007)
410. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. (PubMed id 17613170)^{1, 9} Swellam M....Bushnak H.A. (2007)
411. HER-2/neu expression in glioblastoma multiforme. (PubMed id 17536308)^{1, 9} Haynik D.M....Prayson R.A. (2007)
412. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. (PubMed id 17631500)^{1, 9} Yoon S....Kim K.S. (2007)
413. [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma] (PubMed id 18172343)^{1, 9} Lee S.W....Han S.W. (2007)
414. HER-2 tissue expression correlated with serum levels in breast cancer patients. (PubMed id 17706017)^{1, 9} Pribylova O....Petruzelka L. (2007)
415. Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors. (PubMed id 17848143)^{1, 9} Radovic S....Serdarevic F. (2007)
416. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal. (PubMed id 17612563)^{1, 9} Diehl K.M....Woods-Ignatoski K.M. (2007)
417. HER2 expression as a potential marker for response to therapy targeted to the EGFR. (PubMed id 16622439)^{1, 9} Emlet D.R....Shackney S.E. (2006)
418. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. (PubMed id 16397024)^{1, 9} Lee J.W....Lee S.H. (2006)
419. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. (PubMed id 17016520)^{1, 9} Wolf-Yadlin A....White F.M. (2006)
420. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. (PubMed id 16843263)^{1, 9} Wang S.E....Arteaga C.L. (2006)
421. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. (PubMed id 17132159)^{1, 9} Einarsdottir K....Wedren S. (2006)
422. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. (PubMed id 16490596)^{1, 9} Bizari L....Silva A.E. (2006)
423. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. (PubMed id 16405663)^{1, 9} Mayr D....Diebold J. (2006)
424. Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women. (PubMed id 17393979)^{1, 9} Selvarajan S....Tan P.H. (2006)
425. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. (PubMed id 16682283)^{1, 9} Puputti M....Nupponen N.N. (2006)
426. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. (PubMed id 17150109)^{1, 9} Bekaii-Saab T....Eng C. (2006)
427. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. (PubMed id 15870067)^{1, 9} Begon D.Y....Winkler R. (2005)
428. Integrin alpha6beta4-erbB2 complex inhibits haptotaxis by up-regulating E-cadherin cell-cell junctions in keratinocytes. (PubMed id 15579904)^{1, 9} Hintermann E....Quaranta V. (2005)
429. Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis. (PubMed id 15609325)^{1, 9} Beckers J....Seliger B. (2005)
430. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. (PubMed id 16199884)^{1, 9} Lund C.V....Barbas C.F. (2005)
431. Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells. (PubMed id 15888451)^{1, 9} Hu Y.P....Brattain M.G. (2005)
432. Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation. (PubMed id 16273189)^{1, 9} Freitas L.L....Altemani A. (2005)
433. HER-2 gene amplification can be acquired as breast cancer progresses. (PubMed id 15194824)^{1, 9} Meng S....Uhr J. (2004)
434. A unique structure for epidermal growth factor recept or bound to GW572016 (Lapatinib): relationships among protein conformation, inh ibitor off-rate, and receptor activity in tumor cells. (PubMed id 15374980)^{7, 9} Wood E.R....Shewchuk L. (2004)
435. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein. (PubMed id 15080792)^{1, 9} Li H....Villalobo A. (2004)
436. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. (PubMed id 15561777)^{1, 9} Dragowska W.H....Bally M.B. (2004)
437. Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa. (PubMed id 15120910)^{1, 9} Cianciulli A....Guadagni F. (2004)
438. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck. (PubMed id 15254682)^{1, 9} Do N.Y....Im T.S. (2004)
439. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. (PubMed id 15330164)^{1, 9} Mandoky L....Bak M. (2004)
440. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. (PubMed id 14967461)^{7, 9} Langer C.J. (2004)
441. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. (PubMed id 15235125)^{1, 9} Menendez J.A....Lupu R. (2004)
442. Role of ErbB2 in Corneal Epithelial Wound Healing. (PubMed id 15557433)^{1, 9} Xu K.P....Yu F.S. (2004)
443. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. (PubMed id 14724563)^{1, 9} Al Moustafa A.E....Alaoui-Jamali M.A. (2004)
444. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis. (PubMed id 14580260)^{1, 9} Winters Z.E....Harris A.L. (2003)
445. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. (PubMed id 12529347)^{1, 9} Konecny G....Slamon D.J. (2003)
446. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. (PubMed id 12825853)^{1, 9} Lebeau A....Lohrs U. (2003)
447. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. (PubMed id 12775708)^{1, 9} Martin L.A....Dowsett M. (2003)
448. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. (PubMed id 12517775)^{1, 9} Tikhomirov O. and Carpenter G. (2003)
449. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. (PubMed id 12853564)^{1, 9} Holbro T....Hynes N.E. (2003)
450. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. (PubMed id 12517790)^{1, 9} Hernan R....Gilbertson R.J. (2003)
451. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. (PubMed id 12759537)^{1, 9} Nagler R.M....Ben-Itzhak O. (2003)
452. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. (PubMed id 14520464)^{1, 9} Latif Z....Bartlett J.M. (2003)
453. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma. (PubMed id 14563447)^{1, 9} Mabrouk R.A. and Ali-Labib R. (2003)
454. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. (PubMed id 12517789)^{1, 9} Kumar-Sinha C....Chinnaiyan A.M. (2003)
455. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors. (PubMed id 14628084)^{1, 9} Erdogan S....Tuncer I. (2003)
456. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. (PubMed id 12174876)^{1, 9} Smith V....Kelland L.R. (2002)
457. [Expression and clinical significance of p53 and c-erbB2 in geriatric women with cervical carcinoma] (PubMed id 12451999)^{1, 9} Huang Y.W....Liu F.Y. (2002)
458. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. (PubMed id 12579211)^{1, 9} Ghaderi A....Modjtahedi H. (2002)
459. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. (PubMed id 11891317)^{1, 9} Bajo A.M....Szepeshazi K. (2002)
460. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. (PubMed id 12368191)^{1, 9} Wilson K.S....Geradts J. (2002)
461. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. (PubMed id 12432555)^{1, 9} Kruger S....Bohle A. (2002)
462. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. (PubMed id 12239347)^{1, 9} Xu W....Neckers L. (2002)
463. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. (PubMed id 12174949)^{1, 9} Larsimont D....Gancberg D. (2002)
464. Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. (PubMed id 12198768)^{1, 9} Knosel T....Petersen I. (2002)
465. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. (PubMed id 11986780)^{1, 9} Hirsch F.R....Bunn P.A. (2002)
466. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. (PubMed id 11839675)^{1, 9} Khan A.J....Haffty B.G. (2002)
467. Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity. (PubMed id 10572067)^{1, 9} Fernandes A.M....Gerwin B.I. (1999)
468. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. (PubMed id 9710588)^{1, 9} Olayioye M.A....Hynes N.E. (1998)
469. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. (PubMed id 9705354)^{1, 9} Meng T.C. and Lin M.F. (1998)
470. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. (PubMed id 9590694)^{1, 9} Qiu Y....Kung H.J. (1998)
471. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. (PubMed id 9130710)^{1, 9} Graus-Porta D....Hynes N.E. (1997)
472. Assignment of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) to human chromosome band 17q21.1 by in situ hybridization. (PubMed id 9154120)^{1, 9} Muleris M....Dutrillaux B. (1997)
473. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinom as. (PubMed id 22899400)¹ Anglesio M.S....McAlpine J.N. (2013)
474. Increased hyaluronan content and stromal cell CD44 ass ociate with HER2 positivity and poor prognosis in human breast cancer. (PubMed id 22753277)¹ Auvinen P....Tammi M. (2013)
475. Is it necessary to evaluate nuclei in HER2 FISH evalua tion? (PubMed id 23270898)¹ Lopez C....Lejeune M. (2013)
476. Clinicopathologic characteristics of HER2 FISH-ambiguo us breast cancer at a single institution. (PubMed id 23108020)¹ Clay M.R....Jensen K.C. (2013)
477. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. (PubMed id 21761402)¹ Melhem-Bertrandt A....Arun B.K. (2012)
478. Protein interactions with HER-family receptors can hav e different characteristics depending on the hosting cell line. (PubMed id 22200885)¹ Barta P....Andersson K. (2012)
479. NRF2 inhibition represses ErbB2 signaling in ovarian c arcinoma cells: implications for tumor growth retardation and docetaxel sensitiv ity. (PubMed id 22387177)¹ Manandhar S....Kwak M.K. (2012)
480. Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer. (PubMed id 22552811)¹ Glynn R.W....Kerin M.J. (2012)
481. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. (PubMed id 22388760)¹ Seol H....Park S.Y. (2012)
482. Seventeen-gene signature from enriched Her2/Neu mammar y tumor-initiating cells predicts clinical outcome for human HER2+:ERa- breast c ancer. (PubMed id 22460789)¹ Liu J.C....Zacksenhaus E. (2012)
483. A role of Rab7 in stabilizing EGFR-Her2 and in sustain ing Akt survival signal. (PubMed id 21928319)¹ Wang T....Hong W. (2012)
484. Polymorphism rs4919510:C>G in mature sequence of hu man microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. (PubMed id 22586447)¹ Huang A.J....Shao Z.M. (2012)
485. Human epidermal growth factor receptor-2 gene amplific ation in gastric cancer using tissue microarray technology. (PubMed id 22253521)¹ Tsapralis D....Karamitopoulou E. (2012)
486. Leptin and HER-2 are associated with gastric cancer pr ogression and prognosis of patients. (PubMed id 22883999)¹ Geng Y....Yin Y. (2012)
487. Potential role of HER2-overexpressing exosomes in cou ntering trastuzumab-based therapy. (PubMed id 21465472)¹ Ciravolo V....Pupa S.M. (2012)
488. Cross-talk between HER2 and MED1 regulates tamoxifen r esistance of human breast cancer cells. (PubMed id 22964581)¹ Cui J....Zhang X. (2012)
489. Cap-dependent mRNA translation and the ubiquitin-prote asome system cooperate to promote ERBB2-dependent esophageal cancer phenotype. (PubMed id 22767218)¹ Issaenko O.A....Dahlberg P.S. (2012)
490. HER2 status determination using RNA-ISH--a rapid and s imple technique showing high correlation with FISH and IHC in 141 cases of breas t cancer. (PubMed id 22763874)¹ Alba J....Garcia-Caballero T. (2012)
491. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. (PubMed id 22064554)¹ Liu W....Yu Y. (2012)
492. Factors influencing the hormone receptor and HER2 leve ls in breast cancer: a population-based analysis. (PubMed id 22414972)¹ Tas F. (2012)
493. HER-2/neu-mediated down-regulation of biglycan associa ted with altered growth properties. (PubMed id 22582394)¹ Recktenwald C.V....Seliger B. (2012)
494. Relationships between progesterone receptor isoforms a nd the HER/ErbB receptors and ligands network in 299 primary breast cancers. (PubMed id 22505232)¹ Lindet C....Bonneterre J. (2012)
495. HER2 expression in gastric and gastroesophageal juncti on adenocarcinoma in a US population: clinicopathologic analysis with proposed a pproach to HER2 assessment. (PubMed id 21617522)¹ Kunz P.L....Pai R.K. (2012)
496. Association of HER-2 copy number and HER-2/CEP-17 rati o with neoadjuvant taxane-containing chemotherapy sensitivity in locally advance d breast cancer. (PubMed id 22561335)¹ Yu K.D....Shao Z.M. (2012)
497. Gene expression profiles of phaeochromocytomas with ER BB2 overexpression reveal a new molecular mechanism tumourigenicity. (PubMed id 22429000)¹ Qi Y....Ning G. (2012)
498. Triple-negative phenotype is of adverse prognostic val ue in patients treated with dose-dense sequential adjuvant chemotherapy: a trans lational research analysis in the context of a Hellenic Cooperative Oncology Gro up (HeCOG) randomized phase III trial. (PubMed id 21901395)¹ Skarlos P....Fountzilas G. (2012)
499. HER2-negative (1+) breast cancer with unfavorable prog nostic features: to FISH or not to FISH? (PubMed id 22412042)¹ Iorfida M....Colleoni M. (2012)
500. Analysis of HER2 gene amplification and protein expres sion in esophageal squamous cell carcinoma. (PubMed id 21318736)¹ Zhan N....Xiong C.L. (2012)
501. The EGF receptor and HER2 participate in TNF-a-depende nt MAPK activation and IL-8 secretion in intestinal epithelial cells. (PubMed id 22988345)¹ Jijon H.B....Beck P.L. (2012)
502. Coexpression of p53 and Ki 67 and lack of c-erbB2 expression in oral leukoplakias in India. (PubMed id 22641442)¹ Kumar P....Rathod G.P. (2012)
503. Frequency of driver mutations in lung adenocarcinoma f rom female never-smokers varies with histologic subtypes and age at diagnosis. (PubMed id 22317764)¹ Zhang Y....Chen H. (2012)
504. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. (PubMed id 22584052)¹ Saito M....Watanabe S. (2012)
505. A population-based study of Kurdish breast cancer in n orthern Iraq: hormone receptor and HER2 status. A comparison with Arabic women a nd United States SEER data. (PubMed id 22727195)¹ Runnak M.A....Michael H.D. (2012)
506. Expression of activated type I receptor tyrosine kinas es in early breast cancer. (PubMed id 22562124)¹ Spears M....Bartlett J.M. (2012)
507. ErbB2, EphrinB1, Src kinase and PTPN13 signaling compl ex regulates MAP kinase signaling in human cancers. (PubMed id 22279592)¹ Vermeer P.D....Lee J.H. (2012)
508. Charged linker sequence modulates eukaryotic heat shoc k protein 90 (Hsp90) chaperone activity. (PubMed id 22315411)¹ Tsutsumi S....Neckers L.M. (2012)
509. HER2 status in unusual histological variants of gastri c adenocarcinomas. (PubMed id 22067088)¹ Giuffre G....Tuccari G. (2012)
510. Sorafenib in combination with capecitabine: an oral re gimen for patients with HER2-negative locally advanced or metastatic breast canc er. (PubMed id 22412143)¹ Baselga J....Costa F. (2012)
511. Expression of HER2 and bradykinin B_1 receptors in pre cursor lesions of gallbladder carcinoma. (PubMed id 22468084)¹ Toledo C....Poblete M.T. (2012)
512. HER-2/neu gene amplification in carcinoma ex pleomorph ic adenoma in relation to progression and prognosis: a chromogenic in-situ hybri dization study. (PubMed id 22486195)¹ Hashimoto K....Oda Y. (2012)
513. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. (PubMed id 22476857)¹ Yang Y.L....Fu L. (2012)
514. Activated HER-receptors in predicting outcome of ER-po sitive breast cancer patients treated with adjuvant endocrine therapy. (PubMed id 22854050)¹ Larsen M.S....Rasmussen B.B. (2012)
515. Profiling signalling pathways in formalin-fixed and p araffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, H ER3 and uPAR. (PubMed id 21391216)¹ Berg D....Becker K.F. (2012)
516. Expression profiling during mammary epithelial cell th ree-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogen esis and ErbB2-mediated transformation. (PubMed id 22851698)¹ Yu M....Muthuswamy S.K. (2012)
517. Down regulation of CD24 and HER-2/neu in breast carcin oma cells by activated human dendritic cell. Role of STAT3. (PubMed id 22480875)¹ Hira S.K. and Manna P.P. (2012)
518. MicroRNA-125b down-regulation mediates endometrial can cer invasion by targeting ERBB2. (PubMed id 22460089)¹ Shang C....Meng L.R. (2012)
519. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. (PubMed id 22737248)¹ Nanni P....Lollini P.L. (2012)
520. PGC-1a promotes the growth of ErbB2/Neu-induced mammar y tumors by regulating nutrient supply. (PubMed id 22266114)¹ Klimcakova E....St-Pierre J. (2012)
521. Recycling of EGFR and ErbB2 is associated with impaire d Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH. (PubMed id 22800866)¹ Meijer I.M....van Leeuwen J.E. (2012)
522. Intrinsic and acquired resistance to HER2-targeted the rapies in HER2 gene-amplified breast cancer: mechanisms and clinical implication s. (PubMed id 22471661)¹ Rexer B.N. and Arteaga C.L. (2012)
523. Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. (PubMed id 22451678)¹ Wang Y.N....Hung M.C. (2012)
524. Negative/low HER2 expression alone or combined with E- cadherin positivity is predictive of better prognosis in patients with breast ca rcinoma. (PubMed id 22237715)¹ Karray-Chouayekh S....Mokdad-Gargouri R. (2012)
525. Comprehensive analysis of HER2 expression and gene amp lification in gastric cancers using immunohistochemistry and in situ hybridizati on: which scoring system should we use? (PubMed id 21855114)¹ Park Y.S....Kang Y.K. (2012)
526. Functional isolation of activated and unilaterally pho sphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent sig naling. (PubMed id 22733765)¹ Zhang Q....Landgraf R. (2012)
527. In situ detection of HER2:HER2 and HER2:HER3 protein-p rotein interactions demonstrates prognostic significance in early breast cancer. (PubMed id 21638049)¹ Spears M....Bartlett J.M. (2012)
528. Serum enterolactone and postmenopausal breast cancer r isk by estrogen, progesterone and herceptin 2 receptor status. (PubMed id 21544804)¹ Zaineddin A.K....Chang-Claude J. (2012)
529. Predictive value of HER2 serum levels in patients trea ted with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. (PubMed id 22892393)¹ Witzel I....Muller V. (2012)
530. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopatho logy, diagnostic testing, and clinical implications. (PubMed id 22646280)¹ Hechtman J.F. and Polydorides A.D. (2012)
531. An immunohistochemical study of HER2 expression in men ingioma and its correlation with tumor grade. (PubMed id 22420924)¹ Mahzouni P. and Movahedipour M. (2012)
532. The signaling and transformation potency of the overex pressed HER2 protein is dependent on the normally-expressed EGFR. (PubMed id 21911055)¹ Zhou X. and Agazie Y.M. (2012)
533. Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expre ssion and prognosis in esophageal cancer. (PubMed id 22484976)¹ Schoppmann S.F....Birner P. (2012)
534. Comparing of IRS and Her2 as immunohistochemical scori ng schemes in gastroenteropancreatic neuroendocrine tumors. (PubMed id 22558472)¹ Kaemmerer D....Hommann M. (2012)
535. HER-2/neu gene amplification assessment in breast canc er patients in Isfahan province by real time PCR, differential PCR and immunohis tochemistry. (PubMed id 22326523)¹ Hojati Z. and Orangi E. (2012)
536. Expression and association of HER2 with prognosis in e arly-stage (T1-T2N0M0) non-small cell lung cancer. (PubMed id 22736332)¹ Xia Q....Jang W. (2012)
537. Discovery of novel 5-alkynyl-4-anilinopyrimidines as p otent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases. (PubMed id 22101132)¹ Suzuki N....Wada T. (2012)
538. Fluorescence in situ hybridization mapping of esophage ctomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. (PubMed id 21820152)¹ Brankley S.M....Halling K.C. (2012)
539. Lung adenocarcinomas with HER2-activating mutations ar e associated with distinct clinical features and HER2/EGFR copy number gains. (PubMed id 22071781)¹ Li C....Chen H. (2012)
540. Efficacy and safety of neoadjuvant pertuzumab and tras tuzumab in women with locally advanced, inflammatory, or early HER2-positive bre ast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. (PubMed id 22153890)¹ Gianni L....Valagussa P. (2012)
541. Her-2/neu assessment for gastric carcinoma: validation of scoring system. (PubMed id 22260838)¹ Mrklic I....Tomic S. (2012)
542. The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in c olorectal carcinoma. (PubMed id 22627628)¹ Elezoglu B. and Tolunay S. (2012)
543. MEK inhibition leads to PI3K/AKT activation by relievi ng a negative feedback on ERBB receptors. (PubMed id 22552284)¹ Turke A.B....Engelman J.A. (2012)
544. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. (PubMed id 22139081)¹ Pradeep C.R....Yarden Y. (2012)
545. Clinical implications of pathophysiological and demogr aphic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. (PubMed id 21953571)¹ Gupta M....Girish S. (2012)
546. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. (PubMed id 22464443)¹ Rafn B....Kallunki T. (2012)
547. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. (PubMed id 22577344)¹ Naderi A....Dowhan D.H. (2012)
548. Coordinated expression of oestrogen and androgen rece ptors in HER2-positive breast carcinomas: impact on proliferative activity. (PubMed id 22039288)¹ Lin F.d.e. .M....Carvalho F.M. (2012)
549. Prognostic role and HER2 expression of circulating tum or cells in peripheral blood of patients prior to radical cystectomy: a prospect ive study. (PubMed id 22277196)¹ Rink M....Riethdorf S. (2012)
550. Association of HER2/ErbB2 expression and gene amplific ation with pathologic features and prognosis in esophageal adenocarcinomas. (PubMed id 22252257)¹ Yoon H.H....Sinicrope F.A. (2012)
551. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different si gnalling pathways. (PubMed id 22393391)¹ Jonckheere N....Van Seuningen I. (2012)
552. ERBB2 overexpression triggers transient high mechanoac tivity of breast tumor cells. (PubMed id 22407943)¹ Martin M....Kas J.A. (2012)
553. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. (PubMed id 22325357)¹ De Greve J....Schallier D. (2012)
554. PIK3CA mutations, PTEN, and pHER2 expression and impac t on outcome in HER2-positive early-stage breast cancer patients treated with ad juvant chemotherapy and trastuzumab. (PubMed id 22172323)¹ Jensen J.D....Ewertz M. (2012)
555. Regulatory T cells increase in breast cancer and in st age IV breast cancer. (PubMed id 22116346)¹ Wang Z.K....Jiao S.C. (2012)
556. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-g1 s ignalling in breast cancer cell migration and dissemination. (PubMed id 22262199)¹ Balz L.M....Dittmar T. (2012)
557. The Na+/H+ exchanger NHE1, but not the Na+, HCO3(-) co transporter NBCn1, regulates motility of MCF7 breast cancer cells expressing con stitutively active ErbB2. (PubMed id 22120673)¹ Lauritzen G....Pedersen S.F. (2012)
558. HER-2 expression in immunohistochemistry has no progno stic significance in gastric cancer patients. (PubMed id 22645475)¹ Halon A....Matkowski R. (2012)
559. Efficacy of primed in situ labelling in determination of HER-2 gene amplification and CEN-17 status in breast cancer tissue. (PubMed id 22502695)¹ Salimi M....Majidzadeh-A K. (2012)
560. A case of complete hydatidiform mole in a perimenopaus al woman with diagnostic usefulness of p57(kip2) immunohistochemistry and HER2 f luorescent in situ hybridization. (PubMed id 22197173)¹ Hatanaka K....Tanimoto A. (2012)
561. HER2 evaluation and its impact on breast cancer treatm ent decisions. (PubMed id 21540562)¹ Goddard K.A....Wax C. (2012)
562. HER2/HER3 signaling regulates NK cell-mediated cytotox icity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. (PubMed id 22301547)¹ Okita R....Kiessling R. (2012)
563. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle. (PubMed id 22520071)¹ Liu X....Hnatowich D.J. (2012)
564. A-62176, a potent topoisomerase inhibitor, inhibits th e expression of human epidermal growth factor receptor 2. (PubMed id 22732416)¹ Kim H.L....Kwon Y. (2012)
565. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. (PubMed id 22153616)¹ Nielsen K.V....Mouridsen H.T. (2012)
566. Modeling ductal carcinoma in situ: a HER2-Notch3 colla boration enables luminal filling. (PubMed id 21743488)¹ Pradeep C.R....Yarden Y. (2012)
567. Organotropism and prognostic marker discordance in dis tant metastases of breast carcinoma: fact or fiction? A clinicopathologic analys is. (PubMed id 21840040)¹ St Romain P....Fan F. (2012)
568. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. (PubMed id 22085636)¹ Lebedeva G....Goryanin I. (2012)
569. The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells. (PubMed id 22589551)¹ Li X....Kuwada S.K. (2012)
570. A positive feedback loop between HER2 and ADAM12 in hu man head and neck cancer cells increases migration and invasion. (PubMed id 21986939)¹ Rao V.H....Hansen L.A. (2012)
571. MUC5AC, cytokeratin 20 and HER2 expression and K-RAS m utations within mucinogenic growth in congenital pulmonary airway malformations. (PubMed id 22348416)¹ Rossi G....Rivasi F. (2012)
572. Her-2/neu and topoisomerase IIa in advanced breast can cer: a comprehensive FISH analysis of 245 cases. (PubMed id 22555090)¹ Engelstaedter V....Mayr D. (2012)
573. C-Erb-b2 oncogene expression in intraductal proliferat ive lesions of the breast. (PubMed id 22364303)¹ Eren F....Aydin O. (2012)
574. Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer. (PubMed id 22914212)¹ Balcan E....Cift T. (2012)
575. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. (PubMed id 22760213)¹ Decker T....Gotze K. (2012)
576. [Immunohistochemical study of adhesive molecules Her-2 /neu in nonendometrial carcinoma of corpus uteri]. (PubMed id 22712297)¹ abdulaeva G.M....Gadzhieva S.M. (2012)
577. Transcriptional regulation of the protocadherin b clus ter during Her-2 protein-induced mammary tumorigenesis results from altered N-gl ycan branching. (PubMed id 22665489)¹ Guo H....Pierce M. (2012)
578. Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-c olor in situ hybridization and immunohistochemistry. (PubMed id 22495372)¹ Vershasselt-Crinquette M....Leroy X. (2012)
579. [Different Her-2 status in infiltrative and intraducta l components of the breast cancer]. (PubMed id 22880416)¹ Povilaitite P.E....Petrov A.V. (2012)
580. Gene expression profiling identifies sST2 as an effect or of ErbB2-driven breast carcinoma cell motility, associated with metastasis. (PubMed id 22105364)¹ Gillibert-Duplantier J....Badache A. (2012)
581. HER2 and TOP2A in high-risk early breast cancer patien ts treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. (PubMed id 22240029)¹ Fountzilas G....Arapantoni P. (2012)
582. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. (PubMed id 22394363)¹ Kallel I....Rebai A. (2012)
583. Human epidermal growth factor receptor 2 overexpressio n in breast cancer of patients with anti-Yo--associated paraneoplastic cerebella r degeneration. (PubMed id 22351748)¹ Rojas-Marcos I....Graus F. (2012)
584. Quantification of HER expression and dimerization in p atients' tumor samples using time-resolved Forster resonance energy transfer. (PubMed id 22829865)¹ Ho-Pun-Cheung A....Lopez-Crapez E. (2012)
585. MMP-9 increases HER2/neu expression and alters apoptos is levels in human mammary epithelial cells (HMEC). (PubMed id 22878890)¹ Fatunmbi M....Aronica S.M. (2012)
586. ErbB-2 signals through Plexin-B1 to promote breast can cer metastasis. (PubMed id 22378040)¹ Worzfeld T....Offermanns S. (2012)
587. The hormone receptor, human epidermal growth factor r eceptor 2, and molecular subtype status of individual tumor foci in multifocal/ multicentric invasive ductal carcinoma of breast. (PubMed id 21733550)¹ Choi Y....Park S.Y. (2012)
588. MET activation mediates resistance to lapatinib inhibi tion of HER2-amplified gastric cancer cells. (PubMed id 22238368)¹ Chen C.T....Weiser M.R. (2012)
589. Comparison of two nomograms to predict pathologic comp lete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2 -positive tumors need specific predictors. (PubMed id 22160638)¹ Frati A....Rouzier R. (2012)
590. HER2/neu testing for anti-HER2-based therapies in pati ents with unresectable and/or metastatic gastric cancer. (PubMed id 22569536)¹ Gomez-Martin C....Lopez-Rios F. (2012)
591. Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. (PubMed id 22554477)¹ Thomasson M....Henriksson R. (2012)
592. [Biological behaviour of colon cancer cells transfecte d with C-erbB2 shRNA plasmid]. (PubMed id 22482406)¹ Zhao D.L....Sui Y.X. (2012)
593. Human epidermal growth factor receptor 2 status and in terval breast cancer in a population-based cancer registry study. (PubMed id 22585698)¹ Musolino A....Ardizzoni A. (2012)
594. Hormone status and demographics in early onset breast cancer patients. (PubMed id 22748546)¹ Friend K.E....Feliberti E.C. (2012)
595. Role of C-erbB2 expression in gallbladder cancer. (PubMed id 22499306)¹ Kumari N....Baitha D.K. (2012)
596. A single ligand is sufficient to activate EGFR dimers. (PubMed id 22699492)¹ Liu P....Leahy D.J. (2012)
597. [HER-2/neu-testing in breast cancer: is the immunocyto chemistry competent?]. (PubMed id 22880415)¹ Matsionis A.E....Povilaitite P.E. (2012)
598. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activatio n of ErbB3. (PubMed id 22248472)¹ McDonagh C.F....Nielsen U.B. (2012)
599. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. (PubMed id 22437741)¹ Cho E.Y....Kim S. (2012)
600. The expression of PCNA, c-erbB-2, p53, ER and PR as we ll as atypical hyperplasia in tissues nearby the breast cancer. (PubMed id 22057681)¹ Jia Z....Sheng W. (2012)
601. HER2 expression in breast cancer with nonamplified HER 2 and gains of chromosome 17 centromere. (PubMed id 22417858)¹ Panvichian R....Leelaudomlipi S. (2012)
602. ErbB2/Her-2 regulates the expression of Akt2 in prosta te cancer cells. (PubMed id 21932427)¹ Le Page C....Mes-Masson A.M. (2012)
603. Expression of epidermal growth factors, erbBs, in the nasal mucosa of patients with chronic hypertrophic rhinitis. (PubMed id 22327010)¹ Nguyen K.H....Shibata M. (2012)
604. HER2/neu and Ki-67 expression predict non-invasive rec urrence following breast-conserving therapy for ductal carcinoma in situ. (PubMed id 22361634)¹ Rakovitch E....Paszat L. (2012)
605. [Expression and significance of HER-2/neu mRNA and REC K mRNA in breast carcinoma tissue]. (PubMed id 23189844)¹ Shen B....Feng J.F. (2012)
606. Quantitation of HER2/neu expression in primary gastroe sophageal adenocarcinomas using conventional light microscopy and quantitative i mage analysis. (PubMed id 22646266)¹ Jeung J....Liu C. (2012)
607. Phase II trial of preoperative paclitaxel, gemcitabine , and trastuzumab combination therapy in HER2 positive stage II/III breast cance r: the Korean Cancer Study Group BR 07-01. (PubMed id 22094934)¹ Im S.A....Ha S.W. (2012)
608. HER-2/neu and TOPIIa expression in gastric cancer refl ect disease severity. (PubMed id 22281973)¹ Liu H.Q....Song S. (2012)
609. High serum HER2 extracellular domain levels: correlati on with a worse disease-free survival and overall survival in primary operable b reast cancer patients. (PubMed id 22116318)¹ Kong Y....Xie X. (2012)
610. ER, HER2, and TOP2A expression in primary tumor, synch ronous axillary nodes, and asynchronous metastases in breast cancer. (PubMed id 21667123)¹ Jensen J.D....Laenkholm A.V. (2012)
611. Target-specific, histology-independent, randomized dis continuation study of lapatinib in patients with HER2-amplified solid tumors. (PubMed id 20857170)¹ Galsky M.D....Zaks T.Z. (2012)
612. Her-2/neu gene amplification and over-expression in st omach and esophageal adenocarcinoma: from pathology to treatment. (PubMed id 21783379)¹ Maresch J....Hejna M. (2012)
613. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. (PubMed id 22154363)¹ Ettl T....Schwarz S. (2012)
614. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. (PubMed id 21097718)² Zang Z.J.... Tan P. (2011)
615. Mass spectrometric analysis of lysine ubiquitylation r eveals promiscuity at site level. (PubMed id 21139048)¹ Danielsen J.M....Nielsen M.L. (2011)
616. IQGAP1 protein binds human epidermal growth factor re ceptor 2 (HER2) and modulates trastuzumab resistance. (PubMed id 21724847)¹ White C.D....Sacks D.B. (2011)
617. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. (PubMed id 21426301)¹ Shih A.J....Radhakrishnan R. (2011)
618. Function of erbB receptors and DNA-PKcs on phosphoryla tion of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation. (PubMed id 21723633)¹ Toulany M....Rodemann H.P. (2011)
619. Heterogeneous amplification of ERBB2 in primary lesion s is responsible for the discordant ERBB2 status of primary and metastatic lesio ns in gastric carcinoma. (PubMed id 22092393)¹ Kim M.A....Kim W.H. (2011)
620. Inactivation of Rac1 reduces Trastuzumab resistance i n PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. (PubMed id 21943825)¹ Zhao Y....Yang C. (2011)
621. Expression of activated HER2 in human testes. (PubMed id 21550039)¹ Shin I....Park H.Y. (2011)
622. A proteome-wide, quantitative survey of in vivo ubiqui tylation sites reveals widespread regulatory roles. (PubMed id 21890473)¹ Wagner S.A....Choudhary C. (2011)
623. HER2 overcomes PTEN (loss)-induced senescence to caus e aggressive prostate cancer. (PubMed id 21930937)¹ Ahmad I....Leung H.Y. (2011)
624. [Association of HER2 protein expression with clinicop athologic features and prognosis in Chinese patients with gastric carcinoma]. (PubMed id 21756821)¹ Wu H.M....Lin X.T. (2011)
625. HER2 and TOP2A as predictive markers for anthracyclin e-containing chemotherapy regimens as adjuvant treatment of breast cancer: a me ta-analysis of individual patient data. (PubMed id 21917518)¹ Di Leo A....Buyse M. (2011)
626. Human epidermal growth factor receptor 2 (HER2) in sa livary gland carcinomas. (PubMed id 21670724)¹ Clauditz T.S....Wilczak W. (2011)
627. Serum HER2/ECD value in stage I and II early breast ca ncer: need of a lower cut-off? (PubMed id 22113445)¹ Badzek S....Mihaljevic Z. (2011)
628. The ErbB3 binding protein EBP1 regulates ErbB2 protei n levels and tamoxifen sensitivity in breast cancer cells. (PubMed id 20379846)¹ Lu Y....Hamburger A.W. (2011)
629. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. (PubMed id 21109951)¹ Wei Q....Carlsson J. (2011)
630. Simultaneous measurement of ERa, HER2, and phosphoERK1 /2 in breast cancer cell lines by flow cytometry. (PubMed id 21607585)¹ Bayraktar U.D....Komanduri K.V. (2011)
631. Evaluation of HER2 protein expression in gastric carc inomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 ca ses of tissue microarrays. (PubMed id 21468783)¹ Kim K.C....Park Y.S. (2011)
632. ErbB2 down-regulates microRNA-205 in breast cancer. (PubMed id 21787752)¹ Adachi R....Sakamaki T. (2011)
633. Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evalua te the efficiency of targeted therapy using monoclonal antibodies. (PubMed id 21282108)¹ Gaborit N....PA"legrin A. (2011)
634. Immunohistochemical detection of Her-2/neu overexpress ion in breast carcinoma in Nigerians: a 5-year retrospective study. (PubMed id 22037080)¹ Ugiagbe E.E....Obaseki D.E. (2011)
635. Detection of erbB2 copy number variations in plasma o f patients with esophageal carcinoma. (PubMed id 21481261)¹ Andolfo I....Zollo M. (2011)
636. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients w ith HER2-positive/ER-negative subtype. (PubMed id 21853352)¹ Kim H.J....Noh D.Y. (2011)
637. System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. (PubMed id 21406692)² Rigbolt K.T....Blagoev B. (2011)
638. Detection of HER2 amplification in circulating free D NA in patients with breast cancer. (PubMed id 21427727)¹ Page K....Shaw J.A. (2011)
639. Ubiquitin ligase substrate identification through qua ntitative proteomics at both the protein and peptide levels. (PubMed id 21987572)¹ Lee K.A....Doedens J.R. (2011)
640. A mathematical model for the effects of HER2 over-expression on cell cycle progression in breast cancer. (PubMed id 21814880)¹ Eladdadi A. and Isaacson D. (2011)
641. I^-catenin and Her2/neu expression in rectal cancer: a ssociation with histomorphological response to neoadjuvant therapy and prognosi s. (PubMed id 21538055)¹ Drebber U....VallbAPhmer D. (2011)
642. Many a mickle makes a muckle. Translating a gastric ca ncer phenotype into a bigger thing. (PubMed id 21985847)¹ Blum M.A. and Ajani J.A. (2011)
643. Survivin regulation by HER2 through NF-I_B and c-myc i n irradiated breast cancer cells. (PubMed id 20716114)¹ Papanikolaou V....Tsezou A. (2011)
644. Lactate dehydrogenase, Gleason score and HER-2 overex pression are significant prognostic factors for M1b prostate cancer. (PubMed id 21249322)¹ Yamada Y....Honda N. (2011)
645. Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases. (PubMed id 21396871)¹ Guan B....Zhou X. (2011)
646. HER2 protein and gene variation between primary and m etastatic breast cancer: significance and impact on patient care. (PubMed id 21307144)¹ Fabi A....Mottolese M. (2011)
647. Comparison of hormonal receptor and HER-2 status betw een breast primary tumours and relapsing tumours: clinical implications of prog esterone receptor loss. (PubMed id 21643691)¹ Bogina G....Zamboni G. (2011)
648. Protein secretion in human mammary epithelial cells f ollowing HER1 receptor activation: influence of HER2 and HER3 expression. (PubMed id 21320340)¹ Zhang Y....Zangar R.C. (2011)
649. Assessment of ErbB2 (Her2) in oesophageal adenocarcin omas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. (PubMed id 21516080)¹ Langer R....Walch A. (2011)
650. Truncated ErbB2 expressed in tumor cell nuclei contri butes to acquired therapeutic resistance to ErbB2 kinase inhibitors. (PubMed id 21673090)¹ Xia W....Spector N.L. (2011)
651. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumour s. (PubMed id 21640482)¹ Fleischmann A....Thalmann G.N. (2011)
652. Significance of epidermal growth factor receptor expre ssion in breast cancer. (PubMed id 21104342)¹ Badovinac-Crnjevic T....Vrbanec D. (2011)
653. RIBBON-1: randomized, double-blind, placebo-controlle d, phase III trial of chemotherapy with or without bevacizumab for first-line t reatment of human epidermal growth factor receptor 2-negative, locally recurren t or metastatic breast cancer. (PubMed id 21383283)¹ Robert N.J....O'Shaughnessy J. (2011)
654. Multiple cancer/testis antigens are preferentially ex pressed in hormone-receptor negative and high-grade breast cancers. (PubMed id 21437249)¹ Chen Y.T....Neville A.M. (2011)
655. Systematic and quantitative assessment of the ubiquiti n-modified proteome. (PubMed id 21906983)¹ Kim W....Gygi S.P. (2011)
656. HER2-positive circulating tumor cells in breast cance r. (PubMed id 21264346)¹ Ignatiadis M....Sotiriou C. (2011)
657. ADAM 10 is associated with gastric cancer progression and prognosis of patients. (PubMed id 21259244)¹ Wang Y.Y....Tao H.Q. (2011)
658. Tumor escape and progression of HER-2/neu negative br east cancer under immune pressure. (PubMed id 21453513)¹ Kmieciak M....Manjili M.H. (2011)
659. Involvement of HER-2/neu and metastasis-related prote ins in the development of ileal neuroendocrine tumors. (PubMed id 21445634)¹ Azzoni C....Bordi C. (2011)
660. Genetic alterations and protein expression of HER2 an d chromosome 17 polysomy in breast cancer. (PubMed id 21676436)¹ Zhu X....Zhou X. (2011)
661. [Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breas t cancer patients]. (PubMed id 22340101)¹ Li X....Hu X. (2011)
662. Expression and clinical significance of leptin, the f unctional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis. (PubMed id 21927908)¹ Xu Y.J....Yin Y.M. (2011)
663. Clinical outcome of adjuvant endocrine treatment acco rding to Her-2/neu status in breast cancer. (PubMed id 21321422)¹ James R....Ramaswamy G. (2011)
664. p130Cas promotes invasiveness of three-dimensional Er bB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1. (PubMed id 20961652)¹ Tornillo G....Cabodi S. (2011)
665. Thrombospondin-1 opens the paracellular pathway in pu lmonary microvascular endothelia through EGFR/ErbB2 activation. (PubMed id 21531776)¹ Garg P....Goldblum S.E. (2011)
666. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) a nd non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mu cosa. (PubMed id 22095373)¹ Gunia S....Erbersdobler A. (2011)
667. Hunk is required for HER2/neu-induced mammary tumorig enesis. (PubMed id 21393859)¹ Yeh E.S....Chodosh L.A. (2011)
668. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoa djuvant chemotherapy. (PubMed id 20229175)¹ Ladoire S....Ghiringhelli F. (2011)
669. Phase II study of the antibody drug conjugate trastuz umab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-p ositive breast cancer after prior HER2-directed therapy. (PubMed id 21172893)¹ Burris H.A....O'Shaughnessy J.A. (2011)
670. Expression patterns of ER, HER2, and NM23-H1 in breas t cancer patients with different menopausal status: correlations with metastasi s. (PubMed id 21913743)¹ Dong S.W....Song X. (2011)
671. Assessing the impact of polysomy-17 on HER2 status an d the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67 ) in epithelial ovarian cancer: a tissue microarray study using immunohistochem istry and fluorescent in situ hybridization. (PubMed id 21623202)¹ Lin C.K....Han C.P. (2011)
672. High serum TGF-I+ predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. (PubMed id 20936340)¹ Rhee J....Kim T.Y. (2011)
673. Clinicopathologic significance of HER-2/neu protein e xpression and gene amplification in gastric carcinoma. (PubMed id 21472111)¹ Yan S.Y....Du Y.Q. (2011)
674. Lack of association between HER2 codon 655 polymorphi sm and breast cancer susceptibility was not credible: appraisal of a recent met a-analysis. (PubMed id 20882402)¹ Lu P.H. and Huang X.F. (2011)
675. Estrogen receptor positive operable breast cancer: doe s menopausal status impact on HER2 and progesterone receptor status? (PubMed id 21700456)¹ Wang N....Hu J. (2011)
676. Prognostic and predictive implications of HER2/ERBB2/ neu gene mutations in lung cancers. (PubMed id 21353324)¹ Tomizawa K....Mitsudomi T. (2011)
677. Prognostic implications of altered human epidermal gr owth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictor s of poor outcome. (PubMed id 21709195)¹ Begnami M.D....Soares F.A. (2011)
678. Her-2/neu gene amplification in esophageal adenocarci noma and its influence on survival. (PubMed id 21267790)¹ Thompson S.K....Ruszkiewicz A.R. (2011)
679. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. (PubMed id 21406401)¹ Rudnick S.I....Adams G.P. (2011)
680. Growth differentiation factor 15 (GDF15)-mediated HER 2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. (PubMed id 21803025)¹ Joshi J.P....Nahta R. (2011)
681. Antisense oligodeoxynucleotide targeting HER2 mRNA sen sitized docetaxel in breast cancer treatment. (PubMed id 22014264)¹ Sun J....Duan H. (2011)
682. Tid1, CHIP and ErbB2 interactions and their prognosti c implications for breast cancer patients. (PubMed id 21710689)¹ Jan C.I....Lo J.F. (2011)
683. c-erbB-2 protein expression in astrocytic tumors of t he brain. (PubMed id 21804458)¹ ReszeA8 J....Mariak Z. (2011)
684. TOP2A amplification in the absence of that of HER-2/n eu: toward individualization of chemotherapeutic practice in breast cancer. (PubMed id 21705665)¹ Glynn R.W....Kerin M.J. (2011)
685. HER2 gene amplification in patients with breast cance r with equivocal IHC results. (PubMed id 21836036)¹ Meijer S.L....van de Vijver M.J. (2011)
686. HER-2 protein overexpressing breast cancer without ge ne amplification shows higher hormone receptor expression than HER-2 protein ov erexpressing breast cancer with gene amplification. (PubMed id 19666946)¹ Koo J.S....Yang W.I. (2011)
687. Heterogeneous HER2 gene amplification: impact on pati ent outcome and a clinically relevant definition. (PubMed id 21757600)¹ Bartlett A.I....Bartlett J.M. (2011)
688. Observer prediction of HER2 amplification in HercepTe st 2+ breast cancers as a potential audit instrument. (PubMed id 21884213)¹ Going J.J. (2011)
689. HER2/ErbB2 receptor signaling in rat and human prolac tinoma cells: strategy for targeted prolactinoma therapy. (PubMed id 21106881)¹ Fukuoka H....Melmed S. (2011)
690. Eosinophil peroxidase signals via epidermal growth fa ctor-2 to induce cell proliferation. (PubMed id 21454806)¹ Walsh M.T....Costello R.W. (2011)
691. P16, c-erbB2 and Ki67 immunoexpression in urothelial carcinomas of the bladder. (PubMed id 21655657)¹ Stepan A....Ciurea R. (2011)
692. The prognostic significance of HER2 overexpression in non-small cell lung cancer. (PubMed id 22199341)¹ Takenaka M....Tanaka F. (2011)
693. Carbamazepine promotes Her-2 protein degradation in b reast cancer cells by modulating HDAC6 activity and acetylation of Hsp90. (PubMed id 21082217)¹ Meng Q....Cai L. (2011)
694. Glycoengineered Pichia produced anti-HER2 is comparab le to trastuzumab in preclinical study. (PubMed id 21487242)¹ Zhang N....Zha D. (2011)
695. Determination of her-2/neu by chromogenic in situ hybr idization on borderline (2+) immunohistochemistry cases in carcinoma breast. (PubMed id 21517259)¹ Asif M....Ali Z. (2011)
696. Overexpression of c-erbB-2 and loss of p16 have molec ular diagnostic relevance but no prognostic value in lung cancer. (PubMed id 20237870)¹ Feng X.L....Cheng S.J. (2011)
697. HER-2/neu gene codon 655 (Ile/Val) polymorphism in br east carcinoma patients. (PubMed id 21204706)¹ Sezgin E....Demirhan B. (2011)
698. Tyrosine phosphatases in the HER2-directed motility o f ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. (PubMed id 21483099)¹ Villa-Moruzzi E. (2011)
699. HER2 status in operable breast cancers from Vietnames e women: Analysis by immunohistochemistry (IHC) and automated silver enhanced i n situ hybridization (SISH). (PubMed id 21338271)¹ Thang V.H....Skoog L. (2011)
700. Positive response to trastuzumab in a case of HER2-ove rexpressing metastatic gastric cancer that presented as severe thrombocytopenia. (PubMed id 22104159)¹ Choi J.H....Kim S.T. (2011)
701. Human epidermal growth factor receptor 2 (HER2/neu) su praexpression in the mammary tumors. (PubMed id 22119832)¹ Moise M....Niculescu M. (2011)
702. HER2 genetic heterogeneity in breast carcinoma. (PubMed id 22011446)¹ Ohlschlegel C....Jochum W. (2011)
703. The I^2-adrenergic receptor and Her2 comprise a positi ve feedback loop in human breast cancer cells. (PubMed id 20237834)¹ Shi M....Guo N. (2011)
704. Immunohistochemical COX-2 overexpression correlates w ith HER-2/neu overexpression in invasive breast carcinomas: a pilot study. (PubMed id 21371829)¹ A8iriA9 I.M....KapucuoA9lu F.N. (2011)
705. [Correlation of CerbB-2 to Ki-67 and P53 expressions in hormone-independent breast cancer]. (PubMed id 21354936)¹ Fang Q. and Wang X.F. (2011)
706. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: im plications for immune-based therapies. (PubMed id 22112244)¹ Muraro E....Dolcetti R. (2011)
707. T cell recognition of HLA-A2 restricted tumor antigen s is impaired by the oncogene HER2. (PubMed id 20715101)¹ Mimura K....Kiessling R. (2011)
708. Astrocyte elevated gene-1 induces breast cancer prolif eration and invasion through upregulating HER2/neu expression. (PubMed id 22340175)¹ Zhang X....Zhang M.X. (2011)
709. Preclinical screening of anti-HER2 nanobodies for mol ecular imaging of breast cancer. (PubMed id 21478264)¹ Vaneycken I....Caveliers V. (2011)
710. Prognostic significance of HER2/neu expression in gast ric cancer. (PubMed id 21739203)¹ Ananiev J....Tchernev G. (2011)
711. Target therapy in HER2-overexpressing breast cancer p atients. (PubMed id 21568729)¹ Amodio R....Romano N. (2011)
712. Expression and significance of HER family receptors i n neuroblastic tumors. (PubMed id 21203803)¹ Izycka-Swieszewska E....Limon J. (2011)
713. Calmodulin binds HER2 and modulates HER2 signaling. (PubMed id 21185879)¹ White C.D....Sacks D.B. (2011)
714. YB-1 evokes susceptibility to cancer through cytokine sis failure, mitotic dysfunction and HER2 amplification. (PubMed id 21423216)¹ Davies A.H....Dunn S.E. (2011)
715. Trastuzumab plus chemotherapy in gastric cancer overe xpressing HER-2 and EGFR: a case report. (PubMed id 21346384)¹ Al-Batran S.E....JAoger E. (2011)
716. ERBB2 gene amplification in oral squamous cell malign ancies: a correlation with tumor progression and gene expression. (PubMed id 21531597)¹ Chu F....Shen G. (2011)
717. Familial and sporadic breast cancers: differences in c linical, histopathological, and immunohistochemical features. (PubMed id 20308044)¹ D'Eredita' G....Berardi T. (2011)
718. The human splice variant I916HER2 induces rapid tumor onset in a reporter transgenic mouse. (PubMed id 21559085)¹ Marchini C....Amici A. (2011)
719. SLP-2 overexpression could serve as a prognostic facto r in node positive and HER2 negative breast cancer. (PubMed id 22081131)¹ Cao W....Sun B. (2011)
720. Expression of survivin, CD117, and C-erbB-2 in neuroe ndocrine carcinoma of the uterine cervix. (PubMed id 21633298)¹ Sukpan K....Siriaunkgul S. (2011)
721. Reduced dose and intermittent treatment with lapatini b and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpres sing breast tumor xenografts. (PubMed id 21138857)¹ Rimawi M.F....Schiff R. (2011)
722. Poly (A)+ transcriptome assessment of ERBB2-induced a lterations in breast cell lines. (PubMed id 21731642)¹ Carraro D.M....Brentani R.R. (2011)
723. A UK NEQAS ISH multicenter ring study using the Venta na HER2 dual-color ISH assay. (PubMed id 21173138)¹ Bartlett J.M....Miller K. (2011)
724. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. (PubMed id 21749714)¹ Su Y....Shu X.O. (2011)
725. Ubiquitination and downregulation of ErbB2 and estrog en receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells. (PubMed id 21503962)¹ Suzuki T....Nakamura H. (2011)
726. Correlation of HER 2/neu gene amplification with immu nohistochemistry and other prognostic factors in breast carcinoma. (PubMed id 21935868)¹ Ramadan S.S....CakmakAsi M. (2011)
727. [Evaluation of HER2 protein overexpression in non-mus cle-invasive bladder cancer with emphasis on tumour grade and recurrence]. (PubMed id 21419519)¹ Janane A....Bouzidi A. (2011)
728. Polymalic acid-based nanobiopolymer provides efficien t systemic breast cancer treatment by inhibiting both HER2/neu receptor synthes is and activity. (PubMed id 21303974)¹ Inoue S....Ljubimova J.Y. (2011)
729. p185, an immunodominant epitope, is an autoantigen mi motope. (PubMed id 21566138)¹ Kumar S....Isenberg D.A. (2011)
730. Alternative HER/PTEN/Akt pathway activation in HPV po sitive and negative penile carcinomas. (PubMed id 21407808)¹ Stankiewicz E....Berney D.M. (2011)
731. Clinicopathological and prognostic significance of HE R-2/neu and VEGF expression in colon carcinomas. (PubMed id 21708009)¹ Li Q....Chen P. (2011)
732. A positive cross-regulation of HER2 and ER-I+36 contro ls ALDH1 positive breast cancer cells. (PubMed id 21907803)¹ Kang L....Wang Z.Y. (2011)
733. [Expression of HER-2 and leptin in gastric cancer and their clinical significance]. (PubMed id 22335909)¹ Geng Y.T....Yin Y.M. (2011)
734. Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors. (PubMed id 22199274)¹ Ise N....Goishi K. (2011)
735. Relation between transforming growth factor-b1 express ion, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. (PubMed id 22015652)¹ Ananiev J....Manolova I. (2011)
736. Bacterial cytoplasm production of an EGFP-labeled sing le-chain Fv antibody specific for the HER2 human receptor. (PubMed id 22066531)¹ Lombardi A....Sperandei M. (2011)
737. Her2 amplification status in Iranian breast cancer pat ients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridi sation (FISH). (PubMed id 21790246)¹ Ghaffari S.R....Moossavi S. (2011)
738. HER2 status in gastro-oesophageal adenocarcinomas ass essed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridi zation methods (FISH and SISH). (PubMed id 21323962)¹ Boers J.E....Methorst N. (2011)
739. Impact of protein tyrosine kinase 6 (PTK6) on human e pidermal growth factor receptor (HER) signalling in breast cancer. (PubMed id 21380407)¹ Ludyga N....Aubele M. (2011)
740. Transcriptional and posttranslational up-regulation o f HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. (PubMed id 21385943)¹ Garrett J.T....Arteaga C.L. (2011)
741. ErbB2 and NFkB overexpression as predictors of chemora diation resistance and putative targets to overcome resistance in muscle-invasiv e bladder cancer. (PubMed id 22102915)¹ Koga F....Kihara K. (2011)
742. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. (PubMed id 21971048)¹ Epis M.R....Leedman P.J. (2011)
743. Dual-colour HER2/chromosome 17 chromogenic in situ hy bridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. (PubMed id 21757431)¹ Yan B....Salto-Tellez M. (2011)
744. Multicenter phase III randomized trial comparing doce taxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-lin e chemotherapy for patients with HER2-gene-amplified metastatic breast cancer ( BCIRG 007 study): two highly active therapeutic regimens. (PubMed id 21115860)¹ Valero V....Slamon D.J. (2011)
745. Successful treatment of a patient with HER2-positive m etastatic gastric cancer with third-line combination therapy with irinotecan, 5- fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). (PubMed id 21985855)¹ Weissinger F....Kruger M. (2011)
746. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. (PubMed id 21852536)¹ Grassian A.R....Brugge J.S. (2011)
747. ERBB2 is a target for USP8-mediated deubiquitination. (PubMed id 21044682)¹ Meijer I.M. and van Leeuwen J.E. (2011)
748. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. (PubMed id 21460800)¹ Hu Y....Zhou Z. (2011)
749. Prognostic molecular markers in women aged 35 years o r younger with breast cancer: is there a difference from the older patients? (PubMed id 21642658)¹ Lin C.H....Cheng A.L. (2011)
750. Identification of the coexisting HER2 gene amplificat ion and novel mutations in the HER2 protein-overexpressed mucinous epithelial o varian cancer. (PubMed id 21347793)¹ Lin W.L....Han C.P. (2011)
751. Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. (PubMed id 21755295)¹ Dahl M....Bouchelouche K. (2011)
752. HER2 status in a population-derived breast cancer coh ort: discordances during tumor progression. (PubMed id 20628810)¹ Wilking U....Bergh J. (2011)
753. Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort. (PubMed id 21263059)¹ Klimant E....Onitilo A.A. (2011)
754. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. (PubMed id 21966491)¹ Menju T....Sabe H. (2011)
755. Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain. (PubMed id 20713021)¹ He L....Hristova K. (2011)
756. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific gr owth factors. (PubMed id 21786419)¹ Diermeier-Daucher S....Brockhoff G. (2011)
757. hTERT regulation by NF-I_B and c-myc in irradiated HER 2-positive breast cancer cells. (PubMed id 21627565)¹ Papanikolaou V....Tsezou A. (2011)
758. A molecularly annotated platform of patient-derived xe nografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (PubMed id 22586653)¹ Bertotti A....Trusolino L. (2011)
759. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. (PubMed id 22037875)¹ Zhang Q....Wagner K.U. (2011)
760. Discovery of new molecular subtypes in oesophageal ade nocarcinoma. (PubMed id 21966358)¹ Berg D....Becker K.F. (2011)
761. Neuregulin-1-human epidermal receptor-2 signaling is a central regulator of pulmonary epithelial permeability and acute lung injury. (PubMed id 21247898)¹ Finigan J.H....Kern J.A. (2011)
762. HER-2 positive and p53 negative breast cancers are as sociated with poor prognosis. (PubMed id 21599513)¹ Al-azawi D....Young L. (2011)
763. Threonine 22 phosphorylation attenuates Hsp90 interac tion with cochaperones and affects its chaperone activity. (PubMed id 21419342)¹ Mollapour M....Neckers L. (2011)
764. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extens ive DCIS component. (PubMed id 21095069)¹ Liao N....Wu Y.L. (2011)
765. [Expression of C-erbB-2 and EGFR expression and its r elationship with cell proliferation in nasopharyngeal carcinoma]. (PubMed id 21473138)¹ Zhang Y....Liu Z. (2011)
766. Quantum dots-based double-color imaging of HER2 posit ive breast cancer invasion. (PubMed id 21609713)¹ Liu X.L....Li Y. (2011)
767. Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples. (PubMed id 22022496)¹ Dvorkin-Gheva A. and Hassell J.A. (2011)
768. Potent anti-proliferative effects of metformin on tras tuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor int eractions. (PubMed id 21862872)¹ Liu B....Thor A.D. (2011)
769. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal recept ors and Her2/neu oncoprotein. (PubMed id 22119825)¹ Recareanu F....Pirici E. (2011)
770. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? (PubMed id 21762477)¹ Albergaria A....Schmitt F. (2011)
771. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. (PubMed id 21317877)¹ Koh Y.W....Gong G. (2011)
772. Lack of replication for the association between HER2 I 655V polymorphism and breast cancer risk: a systematic review and meta-analysis. (PubMed id 21474413)¹ Dahabreh I.J. and Murray S. (2011)
773. HER2 codon 655 G-allele is associated with reductions in plasma high-density lipoprotein levels in breast cancer patients treated with tamoxifen. (PubMed id 21997313)¹ Chang N.W....Wu C.T. (2011)
774. Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary brea st tumors. (PubMed id 21708117)¹ Sanz-Pamplona R....Sierra A. (2011)
775. Highly efficient production of anti-HER2 scFv antibod y variant for targeting breast cancer cells. (PubMed id 21538107)¹ Sommaruga S....Prosperi D. (2011)
776. Her-2/neu amplification determined by real-time quanti tative PCR and its association with clinical outcome of breast cancer in Thailan d. (PubMed id 22126548)¹ Chariyalertsak S....Vinyuvat S. (2011)
777. Aberrant expression of the human epidermal growth fac tor receptor 2 oncogene is not a common feature in osteosarcoma. (PubMed id 21292304)¹ Baumhoer D....Nathrath M. (2011)
778. Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women. (PubMed id 21517254)¹ Singhai R....Patil A. (2011)
779. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ER BB2 gene. (PubMed id 21499233)¹ Khoury T....Cheney R.T. (2011)
780. Low frequency of HER2 amplification and overexpressio n in early onset gastric cancer. (PubMed id 21394646)¹ Moelans C.B....van Diest P.J. (2011)
781. HER2 gene amplification occurs frequently in the micr opapillary variant of urothelial carcinoma: analysis by dual-color in situ hybr idization. (PubMed id 21516078)¹ Ching C.B....Hansel D.E. (2011)
782. Targeting trastuzumab-resistant breast cancer cells w ith a lentivirus engineered to bind antibodies that recognize HER-2. (PubMed id 20232140)¹ Zhang K.X....Rennie P.S. (2011)
783. [Detection of human epidermal growth factor receptor 2 gene in invasive breast cancer by fluorescence in situ hybridization and resear ch of its association with tumor characteristics]. (PubMed id 21503112)¹ Su J....Zheng J. (2011)
784. Overexpression of HER2 signaling to WAVE2-Arp2/3 comp lex activates MMP-independent migration in breast cancer. (PubMed id 20419393)¹ Yokotsuka M....Mukai K. (2011)
785. TOPOIIalpha and HER-2/neu overexpression/amplificatio n in Barrett's oesophagus, dysplasia and adenocarcinoma. (PubMed id 20557373)¹ Rossi E....Cestari R. (2010)
786. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patien ts, in the treatment of early-stage breast cancer. (PubMed id 20658263)¹ Yardley D....Hainsworth J. (2010)
787. Endocrine resistance associated with activated ErbB s ystem in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signali ng pathways. (PubMed id 19609946)¹ Ghayad S.E....Cohen P.A. (2010)
788. HER2 silences tumor suppression in breast cancer cell s by switching expression of C/EBPA9 isoforms. (PubMed id 21098707)¹ Arnal-EstapAc A....Gomis R.R. (2010)
789. Increased HER2/neu expression in recurrent hormone re ceptor-positive breast cancer. (PubMed id 19839717)¹ Kaklamani V.G....O'Regan R.M. (2010)
790. [Expression of HER-2/neu oncogene in hepatocellular c arcinoma and the clinical implications]. (PubMed id 20159713)¹ Zhang J.K....Peng J.W. (2010)
791. Clinicopathologic features of non-small-cell lung can cer with EML4-ALK fusion gene. (PubMed id 20183914)¹ Takahashi T....Date H. (2010)
792. Comparison of microarray-based RNA expression with EL ISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of pati ents with breast cancer and relation to outcome. (PubMed id 20204407)¹ Witzel I.D....MA1ller V. (2010)
793. Genome profiling of ERBB2-amplified breast cancers. (PubMed id 20932292)¹ Sircoulomb F....Chaffanet M. (2010)
794. Expression of ErbB-1 and ErbB-2 in meningioma. (PubMed id 20547458)¹ Wickremesekera A....Kaye A.H. (2010)
795. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. (PubMed id 20873988)¹ Geradts J....Barry W.T. (2010)
796. HER-2 signaling, acquisition of growth factor indepen dence, and regulation of biological networks associated with cell transformatio n. (PubMed id 20736364)¹ Bollig-Fischer A....Ethier S.P. (2010)
797. Her2 overexpression is a rare event in anorectal mela noma. (PubMed id 20562656)¹ Helmke B.M....Kern M.A. (2010)
798. Invasive lobular carcinoma with extracellular mucin p roduction and HER-2 overexpression: a case report and further case studies. (PubMed id 20550696)¹ Yu J....Dabbs D.J. (2010)
799. VRK2 inhibits mitogen-activated protein kinase signal ing and inversely correlates with ErbB2 in human breast cancer. (PubMed id 20679487)¹ FernA!ndez I.F....Lazo P.A. (2010)
800. The expression of TRMT2A, a novel cell cycle regulate d protein, identifies a subset of breast cancer patients with HER2 over-express ion that are at an increased risk of recurrence. (PubMed id 20307320)¹ Hicks D.G....Ross D.T. (2010)
801. Integrin-linked kinase has a critical role in ErbB2 m ammary tumor progression: implications for human breast cancer. (PubMed id 20305688)¹ Pontier S.M....Muller W.J. (2010)
802. P53 codon 72 and HER2 codon 655 polymorphisms in Turk ish breast cancer patients. (PubMed id 20380571)¹ Kara N....Bagci H. (2010)
803. HER-2/neu receptor gene status in endometrial carcino mas: a tissue microarray study. (PubMed id 20102407)¹ Xu M....Hui P. (2010)
804. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. (PubMed id 20534991)¹ Miyamoto A....Maesawa C. (2010)
805. c-erbB-2 and the 'triple-state' in early br east carcinomas. (PubMed id 19548127)¹ Sivridis E....Giatromanolaki A. (2010)
806. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. (PubMed id 20068231)² Olsen J.V....Mann M. (2010)
807. Suppression of Her2/neu expression through ILK inhibi tion is regulated by a pathway involving TWIST and YB-1. (PubMed id 20838384)¹ Kalra J....Bally M.B. (2010)
808. Expression of oncogenic K-ras and loss of Smad4 coope rate to induce the expression of EGFR and to promote invasion of immortalized h uman pancreas ductal cells. (PubMed id 20473902)¹ Zhao S....Freeman J.W. (2010)
809. Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a m urine model. (PubMed id 20041268)¹ Amin A.T....Kitano S. (2010)
810. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 gene s and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. (PubMed id 20177704)¹ Bozhanov S.S....Georgieva E.I. (2010)
811. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer. (PubMed id 20185966)¹ Cuadros M....Concha A. (2010)
812. The vulnerability of the heart as a pluricellular par acrine organ: lessons from unexpected triggers of heart failure in targeted Erb B2 anticancer therapy. (PubMed id 20056944)¹ De Keulenaer G.W....Lemmens K. (2010)
813. Ethanol enhances the interaction of breast cancer cel ls over-expressing ErbB2 with fibronectin. (PubMed id 20201928)¹ Xu M....Luo J. (2010)
814. [HER2 ASCO guidelines. The answer to everything?]. (PubMed id 20740285)¹ Burandt E. and Sauter G. (2010)
815. HER-2/AKT expression in upper urinary tract urothelia l carcinoma: prognostic implications. (PubMed id 20651405)¹ Izquierdo L....Alcaraz A. (2010)
816. Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast c ancer. (PubMed id 20164500)¹ Zhang L....Marchetti D. (2010)
817. Qualitative assessment of the progesterone receptor a nd HER2 improves the Nottingham Prognostic Index up to 5 years after breast can cer diagnosis. (PubMed id 20713855)¹ Van Belle V....Neven P. (2010)
818. Novel anti-fatty acid synthase compounds with anti-ca ncer activity in HER2+ breast cancer. (PubMed id 20973802)¹ Oliveras G....Puig T. (2010)
819. Human prostatic acid phosphatase, an authentic tyrosi ne phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell grow th. (PubMed id 20498373)¹ Chuang T.D....Lin M.F. (2010)
820. Issues and updates: evaluating estrogen receptor-alph a, progesterone receptor, and HER2 in breast cancer. (PubMed id 20436503)¹ Allred D.C. (2010)
821. Mechanistic and signaling analysis of Muc4-ErbB2 sign aling module: new insights into the mechanism of ligand-independent ErbB2 activ ity. (PubMed id 20432461)¹ Kozloski G.A....Carraway K.L. (2010)
822. Classification of HER2 receptor status in breast canc er tissues by MALDI imaging mass spectrometry. (PubMed id 20170166)¹ Rauser S....Walch A. (2010)
823. Genetic susceptibility to distinct bladder cancer sub phenotypes. (PubMed id 19692168)¹ Guey L.T....Malats N. (2010)
824. High Notch1 protein expression is an early event in b reast cancer development and is associated with the HER-2 molecular subtype. (PubMed id 20459529)¹ Zardawi S.J....O'Toole S.A. (2010)
825. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization. (PubMed id 20670419)¹ Vogel U.F. (2010)
826. A novel interaction between HER2/neu and cyclin E in breast cancer. (PubMed id 20453888)¹ Mittendorf E.A....Hunt K.K. (2010)
827. Functional Polymorphisms Associated with Disease-Free Survival in Resected Carcinoma of the Esophagus. (PubMed id 20922573)¹ Boonstra J.J....Dinjens W.N. (2010)
828. HER2 Ile655Val polymorphism contributes to breast can cer risk: evidence from 27 case-control studies. (PubMed id 20401632)¹ Lu S....Hao X. (2010)
829. HER2-mediated upregulation of MMP-1 is involved in ga stric cancer cell invasion. (PubMed id 20460098)¹ Bao W....Yang A.G. (2010)
830. High expression of ErbB2 contributes to cholangiocarc inoma cell invasion and proliferation through AKT/p70S6K. (PubMed id 20731018)¹ Treekitkarnmongkol W. and Suthiphongchai T. (2010)
831. Improved prognostic classification of breast cancer d efined by antagonistic activation patterns of immune response pathway modules. (PubMed id 21050467)¹ Teschendorff A.E....Caldas C. (2010)
832. A study of HER2 gene amplification and protein expres sion in gastric cancer. (PubMed id 20696687)¹ Yan B....Salto-Tellez M. (2010)
833. Comparison of core needle biopsy (CNB) and surgical s pecimens for accurate preoperative evaluation of ER, PgR and HER2 status of bre ast cancer patients. (PubMed id 20557310)¹ Tamaki K....Ohuchi N. (2010)
834. Effects of the combined blockade of EGFR and ErbB-2 o n signal transduction and regulation of cell cycle regulatory proteins in breas t cancer cells. (PubMed id 19946741)¹ D'Alessio A....Normanno N. (2010)
835. CEA-, Her2/neu-, BCRP- and Hsp27-positive micropartic les in breast cancer patients. (PubMed id 20592365)¹ Liebhardt S....Toth B. (2010)
836. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiat ion in rectal cancer. (PubMed id 20644561)¹ Ho-Pun-Cheung A....Lopez-Crapez E. (2010)
837. Determination of the Her-2/neu gene amplification sta tus in cytologic breast cancer specimens using automated silver-enhanced in-sit u hybridization (SISH). (PubMed id 20661016)¹ Fritzsche F.R....Bode B. (2010)
838. [Analysis of signalling pathways in formalin-fixed br east cancer tissues]. (PubMed id 20652812)¹ Berg D....Becker K.F. (2010)
839. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. (PubMed id 20459769)¹ Diaz R....Calvo A. (2010)
840. The cooperation between hMena overexpression and HER2 signalling in breast cancer. (PubMed id 21209853)¹ Di Modugno F....NisticA^ P. (2010)
841. Prognostic significance of HER-2/neu expression in pa tients with ductal carcinoma in situ. (PubMed id 20929083)¹ Stackievicz R....Gutman M. (2010)
842. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and der egulates BCL-2 to promote endocrine resistance of breast tumors. (PubMed id 20876285)¹ Cittelly D.M....Jones F.E. (2010)
843. Anti-HER2 immunoliposomes for selective delivery of e lectron paramagnetic resonance imaging probes to HER2-overexpressing breast tum or cells. (PubMed id 20066490)¹ Burks S.R....Kao J.P. (2010)
844. [Intratumoral heterogeneity of HER2 status in breast carcinoma]. (PubMed id 20652266)¹ Ohlschlegel C....Jochum W. (2010)
845. An RNA interference screen identifies metabolic regul ators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. (PubMed id 20160030)¹ Kourtidis A....Conklin D.S. (2010)
846. [Different influence of Her-2 expression on the progn osis in node-positive and node-negative breast cancer]. (PubMed id 21029694)¹ Wang Y....Xie Y.T. (2010)
847. Concomitant expression of HER2 and HIF-1alpha is a predictor of poor prognosis in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501). (PubMed id 21061787)¹ Niibe Y....Hayakawa K. (2010)
848. A conformationally constrained peptidomimetic binds t o the extracellular region of HER2 protein. (PubMed id 20919746)¹ Banappagari S....Satyanarayanajois S.D. (2010)
849. Arecoline induced disruption of expression and locali zation of the tight junctional protein ZO-1 is dependent on the HER 2 expressio n in human endometrial Ishikawa cells. (PubMed id 20604955)¹ Giri S....Firestone G.L. (2010)
850. [The correlation between the expression of PRL-R and ER/PR in breast cancer.] (PubMed id 20335148)¹ Zheng R.H....Tong Q. (2010)
851. Plasma HER2 levels are not associated with cardiac fu nction or hypertrophy in control subjects and heart failure patients. (PubMed id 19540604)¹ Posch M.G....Ozcelik C. (2010)
852. Classification of HER2/neu status in gastric cancer u sing a breast-cancer derived proteome classifier. (PubMed id 21058730)¹ Balluff B....Ebert M.P. (2010)
853. Targeting chromosomal instability and tumour heteroge neity in HER2-positive breast cancer. (PubMed id 20665662)¹ Burrell R.A....Swanton C. (2010)
854. Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast ca rcinomas. (PubMed id 20126619)¹ Gehrau R.C....Koritschoner N.P. (2010)
855. Use of ER/PR/HER2 subtypes in conjunction with the 20 07 St Gallen Consensus Statement for early breast cancer. (PubMed id 20492696)¹ Bauer K....Caggiano V. (2010)
856. Multiplexed assessment of the Southwest Oncology Grou p-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high an d low levels of HER2 are associated with poor outcome. (PubMed id 20150438)¹ Harigopal M....Hayes D.F. (2010)
857. COX-2 activation is associated with Akt phosphorylati on and poor survival in ER-negative, HER2-positive breast cancer. (PubMed id 21078168)¹ Glynn S.A....Ambs S. (2010)
858. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized in vasive breast cancer patients. (PubMed id 20480225)¹ Pierga J.Y....Marty M. (2010)
859. HER2 status of circulating tumor cells in patients wi th metastatic breast cancer: a prospective, multicenter trial. (PubMed id 20859679)¹ Fehm T....Pantel K. (2010)
860. Triple-negative breast cancer. (PubMed id 20473728)¹ Bartsch R....Steger G.G. (2010)
861. Relationship between cyclooxygenase-2 and human epide rmal growth factor receptor 2 in vascular endothelial growth factor C up-regula tion and lymphangiogenesis in human breast cancer. (PubMed id 20608938)¹ Bhattacharjee R.N....Lala P.K. (2010)
862. Multicenter phase II randomized trial evaluating anti angiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. (PubMed id 20652398)¹ Wildiers H....Paridaens R. (2010)
863. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. (PubMed id 19676041)¹ Murphy N.C....Sutherland R.L. (2010)
864. Evaluation of HER-2/neu gene amplification by fluores cence in situ hybridization and immunohistochemistry in saudi female breast can cer. (PubMed id 21036723)¹ Al-Khattabi H....Al-Qahtani M. (2010)
865. Clinical significance of Her2/neu overexpression in u rothelial carcinomas. (PubMed id 20495743)¹ Alexa A....Raica M. (2010)
866. Polymorphisms in the BRCA1 and ABCB1 genes modulate m enopausal hormone therapy associated breast cancer risk in postmenopausal women . (PubMed id 19672706)¹ (2010)
867. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth. (PubMed id 20211985)¹ Caiazza F....Thomas W. (2010)
868. Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease? (PubMed id 19825881)¹ Kwan W....Olivotto I.A. (2010)
869. Matriptase is involved in ErbB-2-induced prostate can cer cell invasion. (PubMed id 20971737)¹ Wu S.R....Lee M.S. (2010)
870. Increasing CD44+/CD24(-) tumor stem cells, and upregu lation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. (PubMed id 21044318)¹ Wang K.H....Tsai E.M. (2010)
871. HER-2 expression correlates with survivin in primary invasive ductal breast cancers. (PubMed id 21198263)¹ Zhang H. and Jin F. (2010)
872. A comparison of HER2/neu gene amplification and its p rotein overexpression between primary breast cancer and metastatic lymph nodes. (PubMed id 20202990)¹ Aoyama K....Kameoka S. (2010)
873. Spatial structure of the transmembrane domain heterod imer of ErbB1 and ErbB2 receptor tyrosine kinases. (PubMed id 20471394)¹ Mineev K.S....Arseniev A.S. (2010)
874. pcDNA3.1(-)-mediated ribozyme targeting of HER-2 supp resses breast cancer tumor growth. (PubMed id 19444644)¹ He P....Lu G.X. (2010)
875. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negat ive metastatic breast cancer. (PubMed id 20585851)¹ Lobo C....GlA1ck S. (2010)
876. Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2. (PubMed id 20193482)¹ Li H.P....Sun Y. (2010)
877. Her-2/neu expression in prostate adenocarcinoma: a sy stematic review and meta-analysis. (PubMed id 20663525)¹ Neto A.S....Del Giglio A. (2010)
878. Changes of HER2 status in circulating tumor cells com pared with the primary tumor during treatment for advanced breast cancer. (PubMed id 20920984)¹ Munzone E....Sandri M.T. (2010)
879. Heterogenous high-level HER-2 amplification in a smal l subset of colorectal cancers. (PubMed id 20656317)¹ Marx A.H....Izbicki J.R. (2010)
880. Coclustering of ErbB1 and ErbB2 revealed by FRET-sens itized acceptor bleaching. (PubMed id 20655838)¹ SzabA^ A....Nagy P. (2010)
881. Jun amino-terminal kinase 1 activation promotes cell survival in ErbB2-positive breast cancer. (PubMed id 20944115)¹ Han J.S. and Crowe D.L. (2010)
882. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. (PubMed id 21155183)¹ Liu L....Shu Y. (2010)
883. erbB2 gene silencing and its effect on PTEN in SACC-8 3 salivary adenoid cystic carcinoma cells. (PubMed id 20878123)¹ Liu X....Rao G. (2010)
884. Inhibitors of HSP90 block p95-HER2 signaling in Trast uzumab-resistant tumors and suppress their growth. (PubMed id 19855434)¹ Chandarlapaty S....Rosen N. (2010)
885. Discovery and verification of protein differences bet ween Er positive/Her2/neu negative breast tumor tissue and matched adjacent nor mal breast tissue. (PubMed id 20087651)¹ Weitzel L.R....Elias A. (2010)
886. [CMTM5 inhibits the tumor cell behavior of prostate c ancer by downregulation of HER2]. (PubMed id 20721248)¹ Xu T....Wang X.F. (2010)
887. Human epidermal growth factor receptor 2 expression i n early breast cancer patients: a Swiss cost-effectiveness analysis of differen t predictive assay strategies. (PubMed id 20364309)¹ Blank P.R....Szucs T.D. (2010)
888. [Association of HER2 genetic heterogeneity with clini copathological characteristics in breast cancer]. (PubMed id 20931533)¹ Yang Y.L....Fu L. (2010)
889. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. (PubMed id 20506359)¹ Ghedini G.C....Pupa S.M. (2010)
890. ErbB2-enhanced invasiveness of H-Ras MCF10A breast ce lls requires MMP-13 and uPA upregulation via p38 MAPK signaling. (PubMed id 20043086)¹ Yong H.Y....Moon A. (2010)
891. Epidermal growth factor receptor and vascular endothe lial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. (PubMed id 20135347)¹ RydAcn L....FernAP M. (2010)
892. Clinical significance of epidermal growth factor rece ptors in non-small cell lung cancer and a prognostic role for HER2 gene copy nu mber in female patients. (PubMed id 20802349)¹ Al-Saad S....Busund L.T. (2010)
893. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. (PubMed id 19919879)¹ Susini T....Scarselli G. (2010)
894. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. (PubMed id 20063318)¹ Li C....Meng S. (2010)
895. Icb-1 Gene expression is elevated in human endometria l adenocarcinoma and is closely associated with HER2 expression. (PubMed id 20569072)¹ Springwald A....Treeck O. (2010)
896. Transcriptional control of the ERBB2 amplicon by ERRa lpha and PGC-1beta promotes mammary gland tumorigenesis. (PubMed id 20961995)¹ Deblois G....GiguA"re V. (2010)
897. Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. (PubMed id 19812598)¹ Ridd K. and Bastian B.C. (2010)
898. Monitoring serum HER2 levels during neoadjuvant trast uzumab treatment within the GeparQuattro trial. (PubMed id 20623180)¹ Witzel I....MA1ller V. (2010)
899. Distribution of molecular breast cancer subtypes amon g Tunisian women and correlation with histopathological parameters: a study of 194 patients. (PubMed id 20850937)¹ Ben Abdelkrim S....Mokni M. (2010)
900. Critical roles of DMP1 in human epidermal growth fact or receptor 2/neu-Arf-p53 signaling and breast cancer development. (PubMed id 21062982)¹ Taneja P....Inoue K. (2010)
901. Lack of HER2 overexpression and amplification in smal l intestinal adenocarcinoma. (PubMed id 21088150)¹ Chan O.T....Wang H.L. (2010)
902. Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the a pical surface and initiation of survival signaling. (PubMed id 20589763)¹ Pfister A.B....Ramsauer V.P. (2010)
903. Patterns of relapse and metastatic spread in HER2-ove rexpressing breast cancer according to estrogen receptor status. (PubMed id 19956951)¹ Park Y.H....Im Y.H. (2010)
904. The prolyl isomerase Pin1 enhances HER-2 expression a nd cellular transformation via its interaction with mitogen-activated protein k inase/extracellular signal-regulated kinase kinase 1. (PubMed id 20179161)¹ Khanal P....Choi H.S. (2010)
905. A Large-scale genetic association study of esophageal adenocarcinoma risk. (PubMed id 20453000)¹ Liu C.Y....Christiani D.C. (2010)
906. [Expressions of human epidermal growth factor receptor 2 and vascular endothelial growth factor in primary or recurrent metastatic bre ast cancers]. (PubMed id 20868598)¹ Wang Z.K....Yang J.L. (2010)
907. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast c ancer patients treated by mastectomy]. (PubMed id 21029696)¹ Wang S.L....Yu Z.H. (2010)
908. Association between gain-of-function mutations in PIK 3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. (PubMed id 19633047)¹ Kataoka Y....Minami H. (2010)
909. Predictors of gefitinib outcomes in advanced non-smal l cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers . (PubMed id 19473722)¹ Tiseo M....Ardizzoni A. (2010)
910. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast canc er cells. (PubMed id 20837468)¹ Long J.S....Pyne N.J. (2010)
911. Alterations of ER, PR, HER-2/neu, and P53 protein exp ression in ductal breast carcinomas and clinical implications. (PubMed id 19657752)¹ Liu C....Lu P. (2010)
912. A meta-analysis on the association of HER-2 overexpre ssion with prognosis in human osteosarcoma. (PubMed id 19709164)¹ Li Y.G. and Geng X. (2010)
913. HER2 polymorphisms and breast cancer in Tunisian wome n. (PubMed id 19929405)¹ Kallel I....RebaA^ A. (2010)
914. Structural basis for high-affinity HER2 receptor binding by an engineered protein. (PubMed id 20696930)² Eigenbrot C.... Hard T. (2010)
915. [Clinical significance of Her-2/neu status in patient s with uterine papillary serous carcinoma]. (PubMed id 20646447)¹ Ren Y.L....Shi D.R. (2010)
916. Copine-III interacts with ErbB2 and promotes tumor ce ll migration. (PubMed id 20010870)¹ Heinrich C....Hynes N.E. (2010)
917. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. (PubMed id 20332114)¹ Haenssen K.K....Reginato M.J. (2010)
918. Resistance to HER2-targeted therapy: mechanisms of tr astuzumab resistance and possible strategies to overcome unresponsiveness to tr eatment. (PubMed id 20972709)¹ Hubalek M....Marth C. (2010)
919. Detection of HER2 amplification using the SISH techni que in breast, colon, prostate, lung and ovarian carcinoma. (PubMed id 20530441)¹ Ramieri M.T....Alo P.L. (2010)
920. HER2 molecular subtype is a dominant subtype of mamma ry Paget's cells. An immunohistochemical study. (PubMed id 20955381)¹ Sek P....Piekarski J.H. (2010)
921. [HER2 expression in gastric cancer in Peru]. (PubMed id 21263759)¹ Beltran GA!rate B. and Yabar Berrocal A. (2010)
922. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. (PubMed id 20159553)¹ Mollapour M....Neckers L. (2010)
923. Role of anti-Her-2 therapy in bladder carcinoma. (PubMed id 20213094)¹ MarA-n A.P....BarA^n M.G. (2010)
924. Cancer genes alterations and HPV infection in oral sq uamous cell carcinoma. (PubMed id 20579853)¹ PopoviA8 B....Milasin J. (2010)
925. Quantitative determination of HER2 expression by conf ocal microscopy assay in CTCs of breast cancer. (PubMed id 20043103)¹ Cao S....Meng S.D. (2010)
926. HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor. (PubMed id 19609744)¹ Ragab S.M....Shams T.M. (2010)
927. KRAS, BRAF, EGFR and HER2 gene status in a Spanish po pulation of colorectal cancer. (PubMed id 20563851)¹ Herreros-Villanueva M....Coma Del Corral M.J. (2010)
928. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. (PubMed id 20881644)¹ Lee S.Y....Park J.Y. (2010)
929. HER2/neu expression correlates with vascular endothel ial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. (PubMed id 19940005)¹ Schoppmann S.F....Birner P. (2010)
930. In vivo evidence of htid suppressive activity on ErbB -2 in breast cancers over expressing the receptor. (PubMed id 20565727)¹ Kurzik-Dumke U....Natali P.G. (2010)
931. Lack of association between HER2 codon 655 polymorphi sm and breast cancer susceptibility: meta-analysis of 22 studies involving 19,3 41 subjects. (PubMed id 20524057)¹ Ma Y....Qin H. (2010)
932. Targeting EGFR/HER2 pathways enhances the antiprolife rative effect of gemcitabine in biliary tract and gallbladder carcinomas. (PubMed id 21087480)¹ Pignochino Y....Leone F. (2010)
933. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial ca rcinomas. (PubMed id 20167054)¹ Gul A.E....Karadayi N. (2010)
934. A single TCR alpha-chain with dominant peptide recogn ition in the allorestricted HER2/neu-specific T cell repertoire. (PubMed id 20042572)¹ Liang X....Krackhardt A.M. (2010)
935. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognos is of breast cancer. (PubMed id 20872355)¹ Papadopoulou E....Kortsaris A. (2010)
936. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. (PubMed id 20805372)¹ Wilson J.R....Eccles D.M. (2010)
937. Association between acquired uniparental disomy and h omozygous mutations and HER2/ER/PR status in breast cancer. (PubMed id 21152100)¹ Tuna M....Amos C.I. (2010)
938. [Impact of p53 protein and HER2 overexpression on surv ival of patients with stage II breast cancer]. (PubMed id 21532285)¹ Liutkauskiene S....Jureniene K. (2010)
939. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-ba sed therapies. (PubMed id 20389136)¹ Fabi A....Mottolese M. (2010)
940. Notch pathway as candidate therapeutic target in Her2 /Neu/ErbB2 receptor-negative breast tumors. (PubMed id 19956862)¹ Hirose H....Mori M. (2010)
941. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. (PubMed id 20446891)¹ Andersson U....Melin B. (2010)
942. Clinical relevance of HER-2/neu overexpression in pat ients with testicular nonseminomatous germ cell tumor. (PubMed id 20209452)¹ Ghavamnasiri M.R....Ghafarzadegan K. (2010)
943. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. (PubMed id 20690807)¹ Cronin K.A....Ballard-Barbash R. (2010)
944. Heterotrimerization of the growth factor receptors er bB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells re sistant to herceptin. (PubMed id 20103628)¹ Huang X....Liu B. (2010)
945. Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. (PubMed id 20838624)¹ Corbo V....Scarpa A. (2010)
946. Multiple genetic copy number alterations in oral squa mous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primar y and metastatic tumours. (PubMed id 20662834)¹ MartA-n-Ezquerra G....Pujol R.M. (2010)
947. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. (PubMed id 19801938)¹ Bhargava R....Dabbs D.J. (2010)
948. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian canc er. (PubMed id 20217132)¹ SchlA1ter B....Voigtmann R. (2010)
949. Inverse correlation of HER2 with MHC class I expressi on on oesophageal squamous cell carcinoma. (PubMed id 20628381)¹ Maruyama T....Kono K. (2010)
950. Expression of epidermal growth factor receptor and HE R-2 in pediatric embryonal brain tumors. (PubMed id 20962551)¹ Patereli A....Karentzou O. (2010)
951. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. (PubMed id 20581867)¹ Chakrabarty A....Arteaga C.L. (2010)
952. Favorable response to doxorubicin combination chemoth erapy does not yield good clinical outcome in patients with metastatic breast c ancer with triple-negative phenotype. (PubMed id 20920367)¹ Yi S.Y....Im Y.H. (2010)
953. HER2 signaling pathway activation and response of bre ast cancer cells to HER2-targeting agents is dependent strongly on the 3D micro environment. (PubMed id 19701706)¹ Weigelt B....Bissell M.J. (2010)
954. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/n eu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) tra nslocation. (PubMed id 19384064)¹ Kazakov D.V....Michal M. (2009)
955. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. (PubMed id 19309522)¹ Rosa F.E....Rogatto S.R. (2009)
956. Lapatinib: a small-molecule inhibitor of epidermal gr owth factor receptor and human epidermal growth factor receptor-2 tyrosine kina ses used in the treatment of breast cancer. (PubMed id 20110044)⁷ Tevaarwerk A.J. and Kolesar J.M. (2009)
957. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. (PubMed id 19339270)¹ Canova C....Brennan P. (2009)
958. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. (PubMed id 19124506)¹ Mavaddat N....Pharoah P.D. (2009)
959. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. (PubMed id 19170196)¹ Shen M....Lan Q. (2009)
960. Brain metastases in patients who receive trastuzumab- containing chemotherapy for HER2-overexpressing metastatic breast cancer. (PubMed id 19225924)¹ Ono M....Fujiwara Y. (2009)
961. Immunohistochemical expression of HER-2/NEU-CERBB-2 i n patients with adenocarcinoma of the stomach. (PubMed id 20076883)¹ Cirne-Lima F.K....Moreira L.F. (2009)
962. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. (PubMed id 19035464)¹ Wan J....Kole R. (2009)
963. Inhibition of mammalian target of rapamycin is requir ed for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. (PubMed id 19934303)¹ Miller T.W....Arteaga C.L. (2009)
964. Prediction of HER2 gene status in Her2 2+ invasive br east cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. (PubMed id 19060846)¹ Chibon F....MacGrogan G. (2009)
965. Association between frequent CpG island methylation and HER2 amplification in human breast cancers. (PubMed id 19168584)¹ Terada K....Ushijima T. (2009)
966. PTEN identified as important risk factor of chronic o bstructive pulmonary disease. (PubMed id 19625176)¹ Hosgood H.D....Lan Q. (2009)
967. [Construction of an eukaryotic plasmid encoding HER2 and screening of a cell line stably expressing clones] (PubMed id 19257987)¹ Xu T.F....Li D. (2009)
968. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. (PubMed id 19364815)¹ Pedersen K....Arribas J. (2009)
969. Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. (PubMed id 19435911)¹ Arias-Romero L.E....Chernoff J. (2009)
970. Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. (PubMed id 19022565)¹ Kim I.Y....Moon A. (2009)
971. Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors. (PubMed id 20030876)¹ Gutteridge E. and Robertson J.F. (2009)
972. Heritable variation of ERBB2 and breast cancer risk. (PubMed id 19336545)¹ Breyer J.P....Smith J.R. (2009)
973. The impact of HER2/neu expression level on response t o the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group St udy I-01 and I-02. (PubMed id 19351776)¹ Benavides L.C....Peoples G.E. (2009)
974. Immunohistochemical comparison of MUC1, CA125, and He r2Neu in invasive micropapillary carcinoma of the urinary tract and typical inv asive urothelial carcinoma with retraction artifact. (PubMed id 19270645)¹ Sangoi A.R....McKenney J.K. (2009)
975. Management of HER2-positive breast cancer in Asia: co nsensus statement from the Asian Oncology Summit 2009. (PubMed id 19880061)¹ Wong N.S....Pritchard K.I. (2009)
976. Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer. (PubMed id 19860576)¹ RebaA^ M....RebaA^ A. (2009)
977. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clini cal trial. (PubMed id 19667268)¹ Pusztai L....Symmans W.F. (2009)
978. Systematic review of HER2 breast cancer testing. (PubMed id 18685491)¹ Cuadros M. and Villegas R. (2009)
979. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. (PubMed id 19223897)¹ Tovey S.M....Edwards J. (2009)
980. ErbB2 resembles an autoinhibited invertebrate epiderm al growth factor receptor. (PubMed id 19718021)¹ Alvarado D....Lemmon M.A. (2009)
981. Regulation of ErbB2 receptor status by the proteasomal DUB POH1. (PubMed id 19436748)¹ Liu H....Urbe S. (2009)
982. The effects of obesity and HER-2 polymorphisms as ris k factors for endometrial cancer in Korean women. (PubMed id 19438491)¹ Tong S.Y....Kwon S.Y. (2009)
983. E-cadherin surface levels in epithelial growth factor -stimulated cells depend on adherens junction protein shrew-1. (PubMed id 19515834)¹ Gross J.C....Starzinski-Powitz A. (2009)
984. The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. (PubMed id 19734843)¹ Subhawong A.P....Meeker A.K. (2009)
985. A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. (PubMed id 19443706)¹ Rodriguez O.C....Albanese C. (2009)
986. The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. (PubMed id 18805633)¹ Liu J.Y....Kao M.C. (2009)
987. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. (PubMed id 19369627)¹ Brunelli M....Bonetti F. (2009)
988. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. (PubMed id 19218427)¹ Ben-Kasus T....Sela M. (2009)
989. Changes in HER2 expression in breast cancer xenograft s after therapy can be quantified using PET and (18)F-labeled affibody molecule s. (PubMed id 19525458)¹ Kramer-Marek G....Capala J. (2009)
990. Increased epithelial stem cell traits in advanced end ometrial endometrioid carcinoma. (PubMed id 20015385)¹ Chang S.J....Wang H.W. (2009)
991. Up-regulation of miR-21 by HER2/neu signaling promote s cell invasion. (PubMed id 19419954)¹ Huang T.H....McManus M.T. (2009)
992. Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study. (PubMed id 18950845)¹ Vega A....Carracedo A. (2009)
993. Cell signaling in endometrial carcinoma: phosphorylat ed 4E-binding protein-1 expression in endometrial cancer correlates with aggres sive tumors and prognosis. (PubMed id 19428047)¹ Castellvi J....Ramon y Cajal S. (2009)
994. Large-scale structural analysis of the classical human protein tyrosine phosphatome. (PubMed id 19167335)¹ Barr A.J.... Knapp S. (2009)
995. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. (PubMed id 19255335)¹ Lennon S....Leyland-Jones B. (2009)
996. Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directional ity during ErbB2-induced tumor-cell migration. (PubMed id 19223396)¹ Meira M....Hynes N.E. (2009)
997. Lack of HER-2 gene amplification in non-Hodgkin lymph oma using chromogenic in situ hybridisation test. (PubMed id 19452317)¹ Szvalb S....Zidan J. (2009)
998. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. (PubMed id 18327638)¹ Lang J.E....Lucci A. (2009)
999. Genetic polymorphisms in the EGFR (R521K) and estroge n receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia. (PubMed id 19636371)¹ Kallel I....RebaA^ A. (2009)
1000. Co-incidental increase in gene copy number of ERBB2 a nd LRIG1 in breast cancer. (PubMed id 19490591)¹ Ljuslinder I....Hedman H. (2009)
1001. Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559. (PubMed id 19486885)¹ Chen H....Chen Z.T. (2009)
1002. Targeting HER2 signaling pathway for radiosensitizati on: alternative strategy for therapeutic resistance. (PubMed id 19923913)¹ No M....Kim I.A. (2009)
1003. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. (PubMed id 19238210)¹ Gandhi J....Gazdar A.F. (2009)
1004. Does HER-2 over-expressing breast cancer have a predi lection to metastasize to the brain? (PubMed id 19447586)¹ Paterson C....Canney P.A. (2009)
1005. Investigating AP-2 and YY1 protein expression as a ca use of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. (PubMed id 20025767)¹ Powe D.G....Ellis I.O. (2009)
1006. Predicting anthracycline benefit: have we made any pr ogress? (PubMed id 19713842)¹ Moretti E....Di Leo A. (2009)
1007. The mannosylated extracellular domain of Her2/neu pro duced in P. pastoris induces protective antitumor immunity. (PubMed id 19878568)¹ Dimitriadis A....Mamalaki A. (2009)
1008. Inhibition of eIF2alpha dephosphorylation inhibits Er bB2-induced deregulation of mammary acinar morphogenesis. (PubMed id 19754954)¹ Sequeira S.J....Aguirre-Ghiso J.A. (2009)
1009. Triple negative breast cancer compared to hormone rec eptor negative/HER2 positive breast cancer. (PubMed id 19003545)¹ Cicin I....Uygun K. (2009)
1010. Genetic mutations associated with cigarette smoking in pancreatic cancer. (PubMed id 19351817)¹ Blackford A....Hruban R.H. (2009)
1011. Breast cancer subtypes based on ER/PR and Her2 expres sion: comparison of clinicopathologic features and survival. (PubMed id 19574486)¹ Onitilo A.A....Mukesh B.N. (2009)
1012. Regulation of epidermal growth factor receptor traffi cking by lysine deacetylase HDAC6. (PubMed id 20029029)¹ Deribe Y.L....Dikic I. (2009)
1013. Transcriptional activation of hTERT in breast carcino mas by the Her2-ER81-related pathway. (PubMed id 19718948)¹ Vageli D....Koukoulis G.K. (2009)
1014. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. (PubMed id 19878579)¹ Zhang Y....Resat H. (2009)
1015. The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag). (PubMed id 19458631)¹ Wenandy L....thor Straten P. (2009)
1016. Study on the different expression of molecular marker s between cardiac cancer and distal gastric cancer and their correlations with clinicopathological features. (PubMed id 19923826)¹ Ye Y.W....Shi Y.Q. (2009)
1017. Crystallization and preliminary crystallographic stud ies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2. (PubMed id 19574641)¹ Liu Y....Teng M. (2009)